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1. Introduction 
The application of preparations to the skin for medical purposes is as old as the history of 
medicine itself, with references to the use of ointments and salves found in the records of 
Babylonian and Egyptian medicine.(López-Castellano & Merino, 2010) The historical 
development of permeation research is well described by Hadgraft & Lane, 2005. Over time, 
the skin has become an important route for drug delivery in which topical, regional or 
systemic effects are desired (Domínguez-Delgado, et al., 2010). Nevertheless, skin 
constitutes an excellent barrier and presents difficulties for the transdermal delivery of 
therapeutic agents, since few drugs possess the characteristics required to permeate across 
the stratum corneum in sufficient quantities to reach a therapeutic concentration in the 
blood. In order to enhance drug transdermal absorption different methodologies have been 
investigated developed and patented (Rizwan et al., 2009). To date many chemical and 
physical approaches have been applied to increase the efficacy of the material transfer across 
the intact skin. These are termed ‘Novel’ due to recent development with satisfactory results 
in the field of drug delivery (Patel et al., 2010). Improvement in physical permeation-
enhancement technologies has led to renewed interest in transdermal drug delivery. Some 
of these novel advanced transdermal permeation enhancement technologies include: 
iontophoresis, electroporation, ultrasound, microneedles to open up the skin and the use of 
transdermal nanocarriers (Díaz-Torres, 2010; Escobar-Chávez & Merino, 2010a). 
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2. Chemical enhancers 
Chemical percutaneous enhancers have long been used to increase the range of drugs that can 
be effectively delivered through the skin (López-Castellano & Merino, 2010). To date, a 
plethora of chemicals have been evaluated as enhancers, but their inclusion in topical or 
transdermal formulations is limited due to fact that the underlying mechanisms of action of 
these agents remain unclear. Although different chemicals are employed by the industry as 
percutaneous enhancers, some of which have several desirable properties, to date none has 
proved to be ideal. An ideal chemical penetration enhancer should have the following 
attributes (Barry, 1983; López- Castellano & Merino, 2010): a) It should be non-toxic, non-
irritating and non-allergenic, b) It should work rapidly, and its activity and duration of effect 
should be both predictable and reproducible, c) It should exert no pharmacological activity 
within the body, d) It should work unidirectionally, e) When removed, the skin’s barrier 
properties should return both rapidly and fully, f) It should be compatible with both excipients 
and drugs, and g) It should be cosmetically acceptable and, ideally, odourless and colourless. 
2.1 Percutaneous penetration routes of drugs 
There are three major potential routes of percutaneous penetration: appendageal, 
transcellular (through the stratum corneum), and intercellular (through the stratum 
corneum) (Figure 1). There is a weight of evidence that suggests that passage through the 
intact stratum corneum constititutes the predominant route by which most molecules 
penetrate the skin, as the appendageal route is characterized by a limited available fractional  
 
Fig. 1. Processes of percutaneous absorption 
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area of 0.1%. In this way, diffusion through the skin is controlled by the particular 
characteristics of the stratum corneum. In order to obtain a sufficient drug flux and, in turn, 
the therapeutical objectives in question, an alternative is to use chemical percutaneous 
enhancers. These substances alter some of the properties of the stratum corneum. (López-
Castellano & Merino, 2010) 
2.2 Direct effects on the skin due to the use of transdermal penetration enhancers 
The lipid–protein-partititioning theory sets out the mechanisms by which enhancers alter 
skin lipids, proteins and/or partitioning behaviour (Barry, 1991): i) They act on the stratum 
corneum intracellular keratin by denaturing it or modifying its conformation, causing 
subsequent swelling and increased hydration; ii) They affect the desmosomes that maintain 
cohesion among corneocytes; iii) They modify the intercellular lipid domains to reduce the 
barrier-like resistance of the bilayer lipids. Disruption to the lipid bilayers can be 
homogeneous when the enhancer is distributed evenly within the complex bilayer lipids, 
but the accelerant is more likely to be heterogeneously concentrated within the domains of 
the bilayer lipids and iv) They alter the solvent nature of the stratum corneum, thus aiding 
the partitioning of the drug or a co-solvent into the tissue.(López-Castellano & Merino, 2010) 
2.3 Indirect effects on the skin due to the use of transdermal penetration enhancers 
Chemical enhancers can produce: a) Modification of the thermodynamic activity of the 
vehicle. The permeation of a good solvent from the formulation, such as ethanol, can 
increase the thermodynamic activity of a drug; b) It has been suggested that, by permeating 
through the membrane, a solvent can ‘drag’ the permeant with it, though this concept is 
somewhat controversial and requires confirmation; c) Solubilising the permeant within the 
donor, especially when solubility is very low, as in the case of aqueous donor solutions, can 
reduce depletion effects and prolong drug permeation.(López-Castellano & Merino, 2010) 
2.4 Classification of percutaneous chemical enhancers 
The classification of percutaneous enhancers is frequently based on the chemical class to which 
the compounds belong. Table 1 shows the principal classes of percutaneous enhancers.  
 
CHEMICAL CLASS COMPOUNDS
Water Water
Sulfoxides and similar chemicals Dimethyl sulfoxide, Dodecyl methyl sulfoxide 
Ureas Urea
Alcohols Ethanol, Caprylic alcohol, Propylene glycol 
Pyrrolidones and derivatives N-methyl-2-pyrrolidone, 2-pyrrolidone 
Azone and derivatives Azone® (1-dodecylazacycloheptan-2-one) 
Dioxolane derivatives SEPA® 
Surfactants (Anionic, Cationic, Nonionic, 
Zwitterionic) 
Sodium lauryl sulfate, Cetyltrimethyl amonium 
bromide, Sorbitan monolaurate, Polisorbate 80, 
Dodecyl dimethyl ammoniopropane sulfate 
Terpenes Menthol, Limonene
Fatty acids Oleic acid, Undecanoic acid 
Table 1. Principal classes of percutaneous enhancers. 
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2.5 Determination of permeation enhancement 
The great majority of studies of the effects of enhancers on skin permeability have been 
carried out by means of in vitro diffusion experiments in which various kinds of diffusion 
cells have been used. The most well-known of these cells are the Franz diffusion systems. 
These cells have two receptor compartments - donor and receptor (donor positioned above 
receptor) – between which the skin is placed. In general, the skin is pretreated with a 
solution of the chemical enhancer to be evaluated. The transdermal flux (J) of drugs can be 
estimated from the slope of the linear region (steady-state portion) of the accumulated 
amount of drug in the receptor compartment versus time plot. Permeation enhancing 
activity, expressed as enhancement ratio of flux (ERflux), is determined as the ratio between 
the flux value obtained with the chemical enhancer and that obtained with the control. A 
number of variables can strongly influence the permeation enhancement of drugs. The most 
important are the skin used in the experiments, temperature, humidity, enhancer 
concentration, vehicle employed and degree of saturation of the drug in the donor and 
receptor compartments. (López-Castellano & Merino, 2010) 
2.6 Uses in topical/transdermal formulations 
Some examples of drugs delivered throughout the skin using chemical enhancer are shown 
in Table 2.  
Drug Chemical enhancer 
Sodium salicylate (Hadgraft et al., 1985; Smith & Irwin, 2000); Sodium 
naproxen (Escobar-Chavez et al., 2005); Ibuprofen (Philips & Michniak,1995; 
Shen et al., 2007); Nonivamide acetate (Fang et al., 1997); Meloxicam (Zhang 
et al., 2009); Flurbiprofen (Ma et al., 2010); Naloxone (Xu et al., 2007); 
Furosemide (Agyralides et al., 2004); Methotrexate (Allan, 1995); Sumatriptan 
succinate (Balaguer-Fernandez et al., 2010).
Azone® 
Sodium naproxen (Escobar-Chavez et al., 2005); Sodium diclofenac (Escribano 
et al., 2003); Lidocaine (Cazares-Delgadillo et al., 2005); Testosterone 
(Hathout et al., 2010); Mometasone furoate (Senyiğit et al., 2009); Ketorolac 
(Amrish et al., 2009).
Transcutol ® 
Haloperidol (Vaddi et al., 2009); Indomethacin (Ogiso et al., 1995); Leuprolide
(Lu et al., 1992). 
Urea 
Tizanidine hydrochloride (Mutalik et al., 2009); Minoxidil (Mura et al., 2009); 
Metopimazine (Bounoure et al., 2008); Nortriptyline hydrochloride (Merino et 
al., 2008; Escobar-Chavez et al., 2011).
Alcohols 
Lidocaine (Lee et al., 2006); Bupranolol (Babu et al., 2008); Propanolol 
(Amnuaikit et al., 2005); Acyclovir (Montenegro et al., 2003).
Pyrrolidones 
Tizanidine hydrochloride (Mutalik et al., 2009); Daphnetin (Wen et al., 2009); 
Nitrendipin (Mittal et al., 2008).
Fatty acids 
Diclofenac (Kigasawa et al., 2009); Nortiptyline hydrochloride (Merino et al., 
2008); Verapamil hydrochloride (Güngör et al., 2008); Minoxidil (Mura et al., 
2009) 
Terpenes 
Retinol (Mélot et al., 2009); Morphine (Monti et al., 2001); Arginine 
vasopressin (Nair&Pachangula, 2003); Insulin (Pillai & Pachangula, 2003); 
Enoxacin (Fang et al., 1998).
Surfactants 
Table 2. Examples of drugs delivered throughout the skin using chemical penetration enhancers. 
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3. Sonophoresis 
Absorption of ultrasonic energy leads to tissue heating, and this has been used with 
therapeutic intent in many conditions. More recently it has been realized that benefit may 
also be obtained from the non-thermal effects that occur as ULTS travels through tissue. 
ULTS therapies can broadly be divided into ‘‘high’’ power and ‘‘low’’ power therapies 
where high power applications include high intensity focused ULTS and lithotripsy, and 
low power encompasses sonophoresis, sonoporation, gene therapy and bone healing. There 
are three distinct sets of ULTS conditions based on frequency range and applications: 1) 
High frequency (3–10 MHz) or diagnostic ULTS, 2) Medium frequency (0.7–3 MHz) or 
therapeutic ULTS, and 3) Low frequency (18 to 100 KHz) or power ULTS. 
3.1 The ultrasound 
The term ultrasonic refers to sound waves whose frequency is >20 KHz. The intensity (I, 
expressed in W/cm2), or concentration of power within a specific area in an ULTS beam, is 
proportional to the square of the amplitude, p, which is the maximum increase or decrease 
in the pressure relative to ambient conditions in the absence of the sound wave. The 
complete relationship is: I= p2/2ρc, where ρ is the density of the medium and c is the speed 
of the sound (in human soft tissue, this velocity is 1540 m/s). The intensity is progressively 
lost when a sound wave passes through the body or is deviated from its initial direction, a 
phenomenon referred to as attenuation. In homogeneous tissue, the attenuation occurs as a 
result of absorption, in which case the sound energy is transformed into heat and scattered. 
The sound waves are produced in response to an electrical impulse in the piezoelectric 
crystal, allowing the conversion of electrical into mechanical or vibrational energy; this 
transformation requires a molecular medium (solid, liquid, or gas) to be effective. The ULTS 
beam is composed of two fields, the ‘‘near field,’’ in the region closest to the transducer face, 
and the ‘‘far field,’’ corresponding to the conical diverging portion of the beam (Figure 2). 
The parameters controlling this configuration of the ULTS beam are principally the 
frequency and the size of transducer. 
3.2 Mechanisms of action 
3.2.1 Cavitation effects 
Cavitation is the formation of gaseous cavities in a medium upon ULTS exposure. The 
primary cause of cavitation is ULTS-induced pressure variation in the medium. Cavitation 
involves both the rapid growth and collapse of a bubble (inertial cavitation), or the slow 
oscillatory motion of a bubble in an ULTS field (stable cavitation). Collapse of cavitation 
bubbles releases a shock wave that can cause structural alteration in the surrounding tissue 
(Clarke et al., 2004) ULTS can generate violent microstreams, which increase the 
bioavailability of the drugs (Tachibana & Tachibana, 1999). Tissues contain air pockets that 
are trapped in the fibrous structures that act as nuclei for cavitation upon ultrasound 
exposure. The cavitational effects vary inversely with ULTS frequency and directly with 
ULTS intensity. Cavitation might be important when low-frequency ULTS is used, gassy 
fluids are exposed or when small gas-filled spaces are exposed. Cavitation occurs due to the 
nucleation of small gaseous cavities during the negative pressure cycles of ULTS, followed 
by the growth of these bubbles throughout subsequent pressure cycles (Tang et al., 2001). 
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Fig. 2. Enhanced permeation by disruption of lipid barrier and cavitation by use of ULTS.  
3.2.2 Thermal effects 
Absorption of ULTS increases temperature of the medium. Materials that possess higher 
ULTS absorption coefficients, such as bone, experience severe thermal effects compared 
with muscle tissue, which has a lower absorption coefficient (Lubbers et al., 2003). The 
increase in the temperature of the medium upon ULTS exposure at a given frequency varies 
directly with the ULTS intensity and exposure time. The absorption coefficient of a medium 
increases directly with ULTS frequency resulting in temperature increase.  
3.2.3 Convective transport 
Fluid velocities are generated in porous medium exposed to ultrasound due to interference 
of the incident and reflected ULTS waves in the diffusion cell and oscillations of the 
cavitation bubbles. Fluid velocities generated in this way may affect transdermal transport 
by inducing convective transport of the permeant across the skin, especially through hair 
follicles and sweat ducts.  
3.2.4 Mechanical effects 
ULTS is a longitudinal pressure wave inducing sinusoidal pressure variations in the skin, 
which, in turn, induce sinusoidal density variation. At frequencies greater than 1 MHz, the 
density variations occur so rapidly that a small gaseous nucleus cannot grow and 
cavitational effects cease. But other effects due to density variations, such as generation of 
cyclic stresses because of density changes that ultimately lead to fatigue of the medium, may 
continue to occur. Lipid bilayers, being self-assembled structures, can easily be disordered 
by these stresses, which result in an increase in the bilayer permeability. This increase is, 
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however, non-significant and hence mechanical effects do not play an important role in 
therapeutic sonophoresis. Thus cavitation induced lipid bilayer disordering is found to be 
the most important cause for ultrasonic enhancement of transdermal transport. 
3.3 Advantages and disadvantages of sonophoresis 
Sonophoresis is capable of expanding the range of compounds that can be delivered 
transdermally. In addition to the benefits of avoiding the hepatic first-pass effect, and higher 
patient compliance, the additional advantages and disadvantages that the sonophoretic 
technique offers can be summarized as follows in Table 3. 
 
Advantages Disadvantages 
Enhanced drug penetration (of selected drugs) over 
passive transport. 
Can be time-consuming to administer. 
Allows strict control of transdermal penetration rates. 
Permits rapid termination of drug delivery through 
termination of ULTS. 
Skin remains intact, therefore low risk of 
introducing infection. 
Less anxiety provoking or painful than injection 
Minor tingling, irritation, and burning 
have been reported (these effects can 
often be minimized or eradicated with 
proper ULTS adjustment (Maloney et 
al., 1992). 
SC must be intact for effective drug 
penetration. 
In many cases, greater patient satisfaction.  
Not immunologically sensitizing.  
Less risk of systemic absorption than injection.  
Table 3. Advantages and disadvantages of using sonophoresis as a physical penetration 
enhancer. 
3.4 Applications of ultrasound 
Table 4 summarizes the research on sonophoresis uses in the transdermal administration of 
drugs. 
 
Anesthetics 
Research Outcome References 
Topical skin penetration of lidocaine Increase in the concentration of 
lidocaine transmitted into rabbit 
subdermal tissues when topical 
application was followed by use of 
ULTS 
Wells et al., 
1977. 
Double blind, vehicle-controlled, 
crossover trial in healthy volunteers 
for lidocaine cream 
No increase in absorption of lidocaine 
cream by using ULTS 
McEnlay et 
al., 1985. 
Trial in healthy volunteers for 
lidocaine oil 
Other variables include differences in 
ULTS frequencies and drug 
concentrations. 
Novak et al., 
1964. 
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Skin lidocaine penetration 250 kHz induced the highest 
penetration of lidocaine. 
Griffin & 
Touchstone, 
1972. 
Anesthetic effect of lidocaine in legs 
of hairless mice 
ULTS in conjunction with a topical 
aqueous lidocaine solution was rapidly 
effective in inducing an anesthetic effect 
in the legs of hairless mice
Tachibana et 
al., 1993 
Sonophoresis of topical benzocaine 
and dibucaine 
No detectable increase in the rate of 
anesthetic penetration
Williams et 
al., 1990. 
Administration of lidocaine 
hydrochloride trandermally on 
healthy volunteers applying 0.5 
MHz ULTS. 
0.5 MHz ULTS in sonophoresis for 
conduction anesthesia using lidocaine 
hydrochloride for a nerve block, it is 
more effective than the 1 Mhz that is 
widely used in clinical situations
Kim et al., 
2007. 
Permeation of procaine 
hydrochloride through cell 
monolayers applying therapeutical 
ULTS. 
Extent and velocity of the permeation of 
procaine hydrochloride through MDCK 
monolayer can be controlled by 
sonophoresis
Hehn et al., 
1996. 
Analgesic and anti-inflammatory 
drugs 
Effect of intensity, mode, and 
duration of ULTS application on the 
transport of three non steroidal anti-
inflammatory drugs (NSAIDs) 
across cellulose membrane and 
hairless rabbit-skin
Demonstrated the synergistic effect of 
temperature and ULTS operation 
parameters on drug transport of 
NSAIDs 
Meshali et 
al., 2008. 
Effect of an ULTS (1 MHz) on 
transdermal absorption of 
indomethacin from an ointment in 
rats 
Intensity and duration of application 
play an important role in the 
transdermal sonophoretic delivery; 
intensity of 0.75 W/cm2 for 10 min was 
most effective for delivering 
indomethacin
Miyazaki et 
al., 1992. 
Study of  the influence of 
ultrasound on percutaneous 
absorption of ketorolac 
tromethamine in vitro across hairless 
rat skin 
A significant increase in permeation of 
ketorolac through rat skin was 
observed with the applied sonication at 
3 W/cm2 when compared with 
permeation at 1 and 2 W/cm2. 
Tiwari et al., 
2004. 
To determine if a ketorolac 
tromethamine (KT) gel solution 
could be administered in vivo via 
phonophoretic transdermal delivery 
using pulsed ULTS by examining its 
anti-inflammatory effects in a rat 
carrageenan inflammation model. 
The transdermal application of KT gel 
using sonophoresis had significant anti-
hyperalgesic and anti-inflammatory 
effects. These findings suggest that the 
transdermal administration of a KT gel 
using sonophoresis with pulsed ULTS 
might be useful for treating acute 
inflammation and pain.
Yang et al., 
2008. 
Application of ultraphonophoresis 
of 5% ibuprofen nurofen gel to 
affected joints of 20 patients.
Analgesic efficacy of transcutaneous 5% 
gel nurofen in osteoarthrosis. 
Serikov et al., 
2007. 
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Examination of therapeutic effects 
of sonophoresis with ketoprofen in 
gel form in patients with 
enthesopathy of the elbow. 
Positive effects of sonophoresis using a 
pharmacologically active gel with 
ketoprofen were shown to be highly 
significant in assessments, objective 
(clinical examination) and subjective 
(interview). The pain symptoms in the 
elbow resolved in most of the patients. 
Cabak et al., 
2005. 
Quantitative study of sodium 
diclofenac (Voltaren Emulgel, 
Novartis) phonophoresis in humans
Previously applied therapeutic ULTS 
irradiation enhances the percutaneous 
penetration of the topical diclofenac gel, 
although the mechanism remains 
unclear 
Rosim et al., 
2005. 
Investigation of in vitro penetration 
and the in vivo transport of 
flufenamic acid in dependence of 
ULTS. 
Using this in vitro model it is possible to 
compare the transdermal delivery of 
commercial flufenamic ointment in 
volunteers. 
Hippius et 
al., 1998. 
Antibiotics  
Effect of ULTS on the delivery of 
topically applied amphotericin B 
ointment in guinea pigs. 
Amphotericin B content in the skin and 
subcutaneous fatty tissues was much 
higher when the drug was delivered in 
the presence of ULTS. 
Rornanenko 
& Araviiskii, 
1991. 
Administration of tetracycline in 
healthy rabbits using 
electrophoresis and sonophoresis 
 
 
It was found that the tissue levels of 
tetracycline administered with the 
modified methods of electro and 
sonophoresis increased with an increase 
in the current density or ULTS 
intensity, the procedure time and 
antibiotic concentration. 
Ragelis et al., 
1981. 
Immunosuppressives  
Investigated the topical transport of 
Cyclosporin A using low-frequency 
US throughout rat skin 
The enhanced skin accumulation of 
Cyclosporin A by the combination of 
low-frequency ULTS and chemical 
enhancers could help significantly to 
optimize the targeting of the drug 
without of a concomitant increase of the 
systemic side effects. 
 
Liu et al., 
2006. 
Evaluation of the efficacy of low 
frequency sonophoresis (LFS) at 
25KHz produced by a sonicator 
apparatus for treatment of alopecia 
areata, melasma and solar lentigo. 
The study showed that LFS, a not 
aggressive technique, enhanced 
penetration of topic agents obtaining 
effects at the level of the epidermis, 
dermis and appendages (intradermal 
delivery), giving better results in the 
treatment of some cosmetic skin 
disorders. 
Santoianni et 
al., 2004. 
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Anticancer drugs  
Application of a method using 
ULTS and nano/microbubbles to 
cancer gene therapy using prodrug 
activation therapy. 
Dramatic reductions of the tumor size 
by a factor of four. 
 
Aoi et al., 
2007. 
Investigation of competitive 
transport across skin of 5-
fluorouracil into coupling gel under 
the influence of ULTS, heat-alone 
and Azone® enhancement. 
Ultrasonication produced a decrease in 
percutaneous drug penetration. This 
effect was due to the diffusive loss of 
the hydrophilic substance 5-fluorouracil 
from the skin surface. 
Meidan et 
al., 1999. 
Insulin  
To determine if the 3x1 rectangular 
cymbal array perform significantly 
better than the 3x3 circular array for 
glucose reduction in hyperglycemic 
rabbits. 
Using the rectangular cymbal array, the 
glucose decreased faster and to a level 
of -200.8±5.9 mg/dL after 90 min. 
Luis et al., 
2007. 
To demonstrate ultrasonic 
transdermal delivery of insulin in 
vivo using rabbits with a novel, low-
profile two-by-two ULTS array. 
For the ULTS-insulin group, the glucose 
level was found to decrease to -132.6 ± 
35.7 mg/dL from the initial baseline in 
60 min 
Lee et al., 
2004. 
The purpose of this study was to 
demonstrate the feasibility of ULTS-
mediated transdermal delivery of 
insulin in vivo using rats with a 
novel, low profile two-by-two US 
array based on the "cymbal" 
transducer. 
For the 60-min ULTS exposure group, 
the glucose level was found to decrease 
from the baseline to -267.5 ± 61.9 
mg/dL in 1 h. Moreover, to study the 
effects of ULTS exposure time on 
insulin delivery, the 20-min group had 
essentially the same result as the 60-min 
exposure at a similar intensity. 
Smith et al., 
2003. 
Corticosteroids  
Determination of the effect of ULTS 
on the transcutaneous absorption of 
dexamethasone. 
A sonophoretic effect occurred with 
dexamethasone when its application 
saturated the skin. 
Saliba et al., 
2007. 
To determine if ULTS enhances the 
diffusion of transdermally applied 
corticosteroids. 
The effects of sonophoresed 
dexamethasone  can be measured in 
terms of reduced collagen deposition as 
far down as the subcutaneous tissue but 
not in the submuscular or subtendinous 
tissue 
Byl et al., 
1993. 
Comparison of effectiveness of 0.4% 
Dexamethasone sodium phosphate 
(DEX-P) sonophoresis (PH) with 
0.4% DEX-P iontophoresis (ION) 
therapy in the management of 
patients with knee joint 
osteoarthritis 
Significant improvement in total 
WOMAC scores was observed in 15 
(60%) and 16 (64%) patients in the PH 
and ION groups respectively, 
indicating no significant difference in 
the improvement rate. 
Akinbo et al., 
2007. 
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Designing a sonophoretic drug 
delivery system to enhance the 
triamcinolone acetonide (TA) 
permeability. 
The highest permeation of TA was 
observed under the ULTS treatment 
conditions of low frequency, high 
intensity, and in continuous mode.
Yang et al., 
2006. 
Cardiotonics 
The sonophoresis of digoxin in vitro
through human and hairless mouse 
skin. 
There was no enhancement of digoxin 
absorption across human skin by ULTS.
Machet et al., 
1996. 
Vasodilators 
Skin penetration enhancement effect 
of ULTS on methyl nicotinate in 10 
healthy human volunteers.
ULTS treatment applied prior to methyl 
nicotinate led to enhanced 
percutaneous absorption of the drug
McEnlay et 
al., 1993. 
Hormones 
Effect of permeation enhancers and 
application of low frequency (LUS) 
and high frequency ultrasound 
(HUS) on testosterone (TS) 
transdermal permeation after 
application of testosterone solid 
lipid microparticles (SLM). 
Skin exposure to HUS or LUS before 
application of 1% dodecylamine for 30 
min had no superior enhancement 
effect over application of either LUS or 
HUS alone. Application of drug loaded 
SLM offered skin protection against the 
irritation effect produced by TS and 1% 
DA.
El-Kamel et 
al., 2008. 
Cicatrizants 
The effectiveness of sonophoresis on 
the delivery of high molecular 
weight (MW) hyaluronan (HA) into 
synovial membrane using an animal 
model of osteoarthritis (OA).
Synovial fluid analysis revealed 
increased absorption and fluorescence 
microscopy showed deeper penetration 
of both HA1000 and HA3000. 
Park et al., 
2005. 
Calcein 
The skin permeation clearance of 
model hydrophilic solutes, calcein 
(MW 623) and-labeled dextrans 
[MW 4400 (FD-4) and MW 38000 
(FD-40)], across the skin under the 
influence of ULTS.
Good correlations were observed 
between the 3H2O flux and solute 
clearances and, unexpectedly, the slope 
values obtained from linear regression 
of the plots were consistent for all 
solutes examined.
Morimoto et 
al., 2005. 
Oligonucleotids
Assessment of the potential of low 
frequency ULTS (20 kHz, 2.4 
W/cm2) in delivering 
therapeutically significant quantities 
of anti-sense oligonucleotides into 
skin. 
Microscopic evaluations using revealed 
heterogeneous penetration into the 
skin. Heterogeneous penetration led to 
the formation of localized transport 
pathways, which occupied about 5% of 
the total exposed skin area.
Tezel et al., 
2004. 
Stimulants 
The effect of low-frequency 
sonophoresis on fentanyl and 
caffeine permeation through human 
and hairless rat skin. 
Discontinuous ULTS mode was found 
to be more effective in increasing 
transdermal penetration of fentanyl 
while transdermal transport of caffeine 
was enhanced by both continuous and 
pulsed mode.
Boucaud et 
al., 2001. 
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Calcium  
Manipulation of the Ca2+ content of 
the upper epidermis by 
sonophoresis across hairless mouse 
SC. 
Sonophoresis at 15 MHz did not alter 
barrier function. 
Menon et al., 
1994. 
Panax notoginseng  
Effect of a therapeutic US coupled 
with a Panax notoginseng gel for 
medial collateral ligament repair in 
rats. 
This study reveals a positive ultrasonic 
effect of Panax notoginseng extract for 
improving the strength of ligament 
repair. 
Ng et al., 
2008. 
Other applications 
i)To study the mechanisms of penetration 
due to US throughout the skin 
 
To demonstrate the calcein 
permeability through the localized 
transport regions (LTRs) from the 
exposure to the 
ULTS/ Sodium lauryl sulphate 
(SLS) system. 
LTRs and the non-LTRs exhibit 
significant decreases in skin electrical 
resistivity relative to untreated skin, 
suggesting the existence of two levels of 
significant skin structural perturbation 
due to ULTS exposure in the presence 
of SLS. 
Kushner IV 
et al., 2004. 
To shed light on the mechanism(s) 
by which low-frequency ULTS (20 
KHz) enhances the permeability of 
the skin. 
Significant fractions (30%) of the 
intercellular lipids of SC were removed 
during the application of low frequency 
sonophoresis. 
Alvarez-
Roman et al., 
2003. 
Investigation of short time 
sonication effects of human skin at 
variable intensities and on the 
dynamics of fluorescein transport 
across the skin. 
A short application of ULTS enhanced 
the transport of fluorescein across 
human skin by a factor in the range of 
2–9 for full thickness skin samples and 
by a factor in the range of 2–28 000 for 
heat-stripped SC samples 
 
Cancel et al., 
2004. 
Use of quantum dots as a tracer and 
confocal microscopy and 
transmission electron microscopy 
(TEM) as visualization methods, on 
low frequency sonophoresis. 
ULTS significantly increased the 
frequency of occurrence of the otherwise 
scattered and separated lacunar spaces 
in the SC. A significant increase in 
lacunar dimensions was observed when 
1% w/v sodium lauryl sulfate was 
added to the coupling medium. 
 
Paliwal et al., 
2006. 
ii)Kelloids  
ULTS therapy with a water-based 
gel alone 
"Complete flattening" of keloids in two 
young men when 1 MHz at 0.8 W/cm 2 
was applied for approximately 4 
minutes. 
Walker, 1983. 
iii) Tumours  
Optimization of ULTS parameters 
for in vivo bleomycin delivery 
An effective antitumor effect was 
demonstrated in solid tumors of both 
murine and human cell lines. 
Larkin et al., 
2008. 
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Table 4. Research on uses of sonophoresis to administer different drugs through the skin 
4. Iontophoresis 
Transdermal iontophoresis consists of the application of a low density current and low 
voltage (typically 0.5 A/cm2) via an electrical circuit constituted by two drug reservoirs 
(anode and cathode) deposited on skin surface. During application of the current, the drug 
is repelled by the corresponding electrode and pushed through the stratum corneum. A 
substance can pass through the skin by electromigration, electroosmosis or passive 
diffusion. The latter of the three mechanisms is a result of changes caused by the electric 
field to the permeability of the skin, and its effects are negligible compared with those of the 
other two mechanisms. When ions are repelled by the electrode of the same charge and 
attracted by the electrode of the opposite charge is electromigration. When neutral 
substances are transported with the solvent flow is electroosmosis, which at physiological 
pH favours the movement from the anode to the skin.  
The advantages and disadvantages that the iontophoretic technique offers are summarized 
in Table 5. 
4.1 Mechanisms of action 
Skin is a complex membrane and controls the movement of molecules across it in the 
presence of an electric field. Skin has an isoelectric point (pI) of 4–4.5. Above this pH, the 
carboxylic acid groups are ionized. Therefore, at higher pH values, the skin behaves as a 
permselective membrane which especially attracts cations that have been repelled by the 
anode, thus favouring the passage of molecules by electromigration (Merino et al., 1999). 
The movement of small sized cations (mainly Na+) generates a solvent flow that promotes 
the passage of non-charged molecules through the skin. This process is identified as 
electroosmosis (Delgado-Charro and Guy, 1994). Electrical mobility decreases with 
Investigation of high-intensity 
focused ULTS (HIFU) exposure of 
(111) In-MX-B3. 
The HIFU exposure shortened the peak 
tumor uptake time (24 vs. 48 h for the 
control) and increased the peak tumor 
uptake value (38 vs. 25 %ID/g for the 
control). The HIFU effect on enhancing 
tumor uptake was greater at earlier 
times up to 24 h. 
Khaibullina 
et al., 2008. 
Supurative wounds  
Treatment of suppurative wounds 
with ULTS. 
sonophoresis of ethylenediaminetetra 
acetic acid with the quinoxaline 
antibiotic dioxidine was effective in 
accelerating wound purification an 
delimination of necrotic issues 
Levenets et 
al., 1989. 
Treatment of suppurative wounds 
with ULTS. 
Sonophoresis of a 1% papain solution 
together with dimethyl sulfoxide was 
an effective method for treating 
purulent wounds and inflammatory 
infiltrates. 
Matinian et 
al., 1990. 
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molecular weight, and, as a consequence, the electroosmotic contribution becomes 
increasingly important for larger molecules (Guy et al., 2000). The dependence of 
iontophoretic flux on the intensity of the current applied has been clearly demonstrated by 
Faraday's law (Sage et al., 1992): where Ja is the flux (in moles per unit time), ta is the 
transport number, Za is the valence of ion a, I is the current applied (Amperes), and F is 
Faraday's constant (Coulombs/mol). The transport number, ta, is the fraction of the total 
current transported by a specific ion, and is a measure of its efficiency as a charge carrier: 
ta=Ia / I. It follows that knowledge of a compound's transport number allows the feasibility 
of its iontophoretic delivery or extraction to be predicted. The sum of the transport numbers 
of all the ions present during iontophoresis equals 1 (Σti=1), illustrating the competitive 
nature of electrotransport.  
 
Advantages Disadvantages 
Enhance penetration of ionized and unionized 
molecules. Moreover, improving the delivery of 
polar molecules as well as high molecular weight 
compounds (e. g. peptides and oligonucleotides). 
Enabling continuous or pulsatile delivery of drug 
(depending on the current applied). 
Permitting easier termination of drug delivery. 
Offering better control over the amount of drug 
delivered since the amount of compound delivered 
depends on applied current, duration of applied 
current, and area of skin exposed to the current. 
Restoration of the skin barrier functions without 
producing severe skin irritation. 
Ability to be used for systemic delivery or local 
(topical) delivery of drugs. 
Reducing considerably the inter and intraindividual
variability, since the rate of drug delivery is more 
dependent on applied current than on stratum 
corneum characteristics. 
Can be time-consuming to administer. 
The actual current density in the follicle 
maybe high enough to damage growing 
hair. SC must be intact for effective 
drug penetration. 
Table 5. Advantages and disadvantages of using iontophoresis as a physical penetration 
enhancer. 
4.2 Types of iontophresis 
4.2.1 Direct iontophoresis 
Direct iontophoresis can be anodal if the drug is neutral or positively charged and cathodal 
if the drug is negatively charged. Although cations have better properties for iontophoresis, 
anions can also increase their transdermal drug flux with respect to passive diffusion. 
4.2.2 Reverse iontophoresis 
Reverse iontophoresis across the skin is a potentially useful alternative for non-invasive 
clinical and therapeutic drug monitoring. During current application, reverse iontophoresis 
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allows the movement of neutral and positively charged entities into the cathode while 
negatively charged entities move into the anode. The main problem with this is that skin 
contains some of the entities to be analyzed, which implies that there is a period of time 
within which it is necessary to withdraw skin reserves and after which it is possible to 
correlate extracted levels of the analytes with levels in the blood (Leboulanger et al., 2004).  
4.3 Applications of iontophoresis 
The most extended uses of iontophoresis are the treatment of palmoplantar hyperhidrosis 
and the diagnosis of cystic fibrosis. However, iontophoresis is also used for the topical 
delivery of others drugs such as lidocaine, acyclovir and dexamethasone. The only system 
commercially available at present is the fentanyl iontophoretic transdermal system. It is 
indicated for the shortterm management of acute postoperative pain in adult patients 
requiring opioid analgesia during hospitalization. Currently, the iontophoretic delivery of 
apomorphine for the treatment of idiopathic Parkinson’s disease is being evaluated in 
human subjects. Peptide drugs including various series of amino acid derivatives and 
tripeptides, thyrotropin release hormones, LHRH and analogues, vasopressin and calcitonin 
can also be administered by means of this technique. One peptide that has focused the 
attention of researchers in the field of iontophoresis is insulin.  
5. Electroporation 
Electroporation is the phenomenon in which cell membrane permeability to ions and 
macromolecules is increased by exposing the cell to short high electric field pulses. The 
increase in permeability is attributed to the electric field induced “breakdown” of the cell 
membrane and the formation of nano- scale defects or “pores” in the membrane – and hence 
electro-“poration”. Electroporation can be of two types - reversible and irreversible. In 
irreversible electroporation the electric field is such that the membrane permeabilization 
leads to cell death. This may be caused by either permanent permeabilization of the 
membrane and cell lysis (necrosis) or by temporary permeabilization of a magnitude which 
can cause a severe disruption of the cell homeostasis that can finally results in cell death, 
either necrotic or apoptotic. In reversible electroporation the electric pulse causes only a 
temporary increase in permeability and the cell survives. The reversible electroporation 
mode has numerous applications in biotechnology and medicine both, in vitro and in vivo. 
Irreversible electroporation has applications in the food industry, for sterilization and in 
medicine for tissue ablation (Ball et al., 2010). 
5.1 Mechanisms of transdermal electroporation 
The theory postulates two paths for electroporation induced transdermal transport, through 
pores formed in the multiple lipid bilayers connecting corneocytes and through appendage 
cells. Small lipid-soluble molecules can partition into the SC, and then diffuse across the 
lipid bilayer membranes, but water soluble molecules, particularly charged molecules, 
cannot penetrate significantly by this route. High voltage pulsing (> 50V) creates aqueous 
pathways (“pore”) through stratum corneum (SC) lipid bilayer membranes, and short 
pathway segments are formed across 5--6 lipid bilayer membranes which connect adjacent 
corneocyte interiors forming transcellular straight-through pathways. Moderate voltage (= 5 
www.intechopen.com
 Pharmacology 
 
412 
to 50V) pulses appear to electroporate cell linings of the appendages. Temperature is 
considered to play a role in the permeabilization.  
5.2 Advantages and disadvantages of electroporation for transdermal drug delivery 
The advantages and disadvantages that the electroporation technique offers are summarized 
in Table 6. 
 
Advantages Disadvantages 
Enhanced drug penetration (of selected drugs) over 
passive transport. 
Allows strict control of transdermal penetration rates.
Versatility: electroporation is effective nearly with all 
cells and species types (Sung et al., 2003). 
Efficiency: a large majority of cells take in the target 
DNA or molecule (Huang et al., 2005). 
Permits rapid termination of drug delivery through 
termination of electroporation. 
The procedure may be performed with intact tissue 
(Heller et al., 1996). 
Less anxiety provoking or painful than injection. 
In many cases, greater patient satisfaction. 
Cell damage: If the pulses are of the 
wrong length or intensity, some 
pores may become too large or fail 
to close after membrane discharge 
causing cell damage or rupture 
(Murthy et al., 2004). 
The transport of material into and 
out of the cell during the time of 
electropermeability is relatively 
nonspecific (Murthy et al., 2004). 
Not immunologically sensitizing.  
Table 6. Advantages and disadvantages of using electroporation as a physical penetration 
enhancer. 
5.3 Applications of electroporation 
The field of skin electroporation is made of two aspects. The first deal with electroporation 
in a conventional sense in relation to the cells of the skin and the second is unique and 
relates to transdermal effects. The concept of transdermal electroporation may be traced to 
fundamental research on the breakdown of flat lipid bilayer membranes. Prausnitz et al., 
(1993) addresses the fact that transdermal transport normally occurs primarily through the 
intracellular lipids organized in bilayers. Small molecular weight lipophilic drugs can be 
effectively delivered by passive transdermal delivery. However, the stratum corneum does 
not permit passage of polar/hydrophilic molecules and macromolecules. The paper 
suggests that microsecond to millisecond electroporation type pulsed electric fields applied 
across the skin produce, in a manner similar to that found in studies on flat lipid bilayers, 
trans bilayer aqueous pores. It reports that electroporation produces transient structural 
changes in the skin resulting in an up to four orders of magnitude increase in transdermal 
mass transfer flux of polar molecules in human skin in vitro and animal skin in vivo.  
6. Microneedles 
The use of microneedles is another method for bypassing the stratum corneum barrier, 
which have been introduced as a form of transdermal drug delivery. They can penetrate the 
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upper layer of the skin without reaching the dermis, to be an efficient method to deliver drugs 
transdermally in an almost painless method. The drug diffuses across the rest of the epidermis 
into the dermis where it is absorbed into the blood circulation. Nowadays different types of 
microneedles have been designed by other researchers as well, varying in their materials of 
fabrication, shapes, dimensions, modes of application, etc. (Chabri et al., 2009). 
6.1 Microneedle types and their methods of transdermal delivery 
Microneedles are available as both solid and hollow microneedles made of various materials 
(Figure 3). Till date, five methods of transdermal delivery mediated by microneedles have 
been attempted (Gill & Prausnitz, 2007): Poke with patch approach: It can be inserted into the 
skin to pierce the stratum corneum and create micro conduits through which drug can enter 
into the lower layers of the epidermis (Henry et al., 1998). Coat and poke approach: It involves 
coating the drug to be delivered around the surface of the microneedle. By inserting the 
microneedles through the skin, the drug coating dissolves off in the skin fluid and the 
dissolved drug diffuses through the skin into the blood microcirculation. The coating 
methods are used to roll coating, spray coating and dip coating (Gill & Prausnitz, 2006). Dip 
and scrape: The dip and scrape method involves placing the array in contact with the drug 
solution and then scraping multiple times across the skin to create microabbrassions 
(Mikszta et al., 2002). Dissolving microneedles: It is referred to microneedles made from a 
biodegradable polymeric material with the drugs encapsulated inside them. In this method, 
the drug is released in a controlled manner as the microneedle dissolves off when inserted 
into the skin (Lee W. J et al., 2007). Injection through hollow microneedles: This occurs where 
the microneedles are designed with holes at the centre or with side openings through which 
drugs are microinjected into the lower layers of the skin and then diffuses across the viable 
skin until it reaches the blood vessels in the dermis (Griss & Stemme, 2003).  
Solid microneedles: These are easier to fabricate, have better mechanical strength and 
sharper tips as compared to hollow microneedles (Rhoxed et al., 2008a). Solid silicon 
microneedles have been widely used for the transdermal drug delivery studies (Donnelly et 
al., 2009; Haq et al., 2009). However, silicon is expensive, not biocompatible and brittle. 
Therefore it breaks easily during the penetration across skin (Chen et al., 2008). Polymer has 
been used as an alternative material because it is a cheaper and stronger material which 
could reduce tissue damage (Fernandez et al., 2009). Polymer increases the bluntness of the 
microneedle tip due to the low modulus and yield strength of polymer. Polymer 
microneedles have a main limitation with its mechanical properties which could cause 
needle failure during the penetration across skin (Park et al., 2007). Bevelled tip 
microneedles have been fabricated using biodegradable polymers (Park, 2004). Metal is the 
third material used to manufacture microneedles. It is mechanically strong and relatively 
cheap to produce.  
Hollow microneedles: The purpose of this type of microneedles is to deliver drugs through 
the bore at the needle tip. This reduces the sharpness of needle tip which affect the 
penetration of this needle into skin. These issues have been resolved recently including 
openings at the side in the microneedles rather than at the bottom (Roxhed et al., 2008). 
These microneedles have their tip closed initially; however they can be opened on insertion 
into the skin where the tip dissolves in the high saline solution in the interstitial fluid. The 
tips can also be opened as a result of applied pressure. It has been proposed the use of 
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rotary drilling and mechanical vibration as methods to enhance insertion of hollow 
microneedles and the fluid infusion flow rate (Wang et al., 2006).  
 
Fig. 3. Two dimensional view of hollow and solid microneedle.  
6.2 Microneedles manufacturing 
The methods that have been adopted for microneedle fabrication include wet etching, deep 
reactive ion etching (DRIE) (Teo et al., 2005), microinjection moulding (Sammoura et al., 
2007), isotropic etching, isotropic etching in combination with deep etching and wet etching 
respectively, dry etching, isotropic and anisotropic, photolithography, thin film deposition 
(Moon & Lee, 2003), laser cutting (Martanto et al., 2004), and inclined LIGA process 
(Perennes et al., 2006). Studies have shown that factors such as microneedle geometry, 
coating depth on solid microneedle and skin thickness affect the drug delivery efficiency 
using microneedles (Al-Qallaf et al., 2009a; 2009b). To ensure that both the insertion and 
delivery occur at the right location, they should be sharp enough and at least 100μm in 
length (Stoeber & Liepmann, 2000).  
6.3 Microneedles applications 
Vaccination against virus: Researchers have recently presented microneedle patches as a 
better alternative for immunization. The vaccine can be coated unto microneedle array and 
presented as a simple patch which can allow patients to immunize themselves without the 
necessity for intense medical training (Stoeber & Liepmann, 2005). Cutaneous fluid extraction 
and glucose monitoring: A prototype of a disposable microneedle based glucose monitoring 
devices has been designed in which, the fluid extraction chamber attached to the 
microneedle can be connected to a sensing device which measures and indicates the glucose 
concentration in the body (Zimmermann et al., 2003). Acne treatment: The treatment is 
limited by the low rate of penetration of drugs through the stratum corneum. So, 
experiments have been carried out by applying the TheraJectMATTM dissolving 
microneedles containing API in a GRAS matrix to the surface of human skin with acne 
(Kwon, 2006). Delivery of nanoparticles: It was showed that the delivery of particles of 1μm in 
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diameter is enhanced when the skin is pre-treated with microneedles by adopting the poke 
with patch approach. Therefore, it seems to us that the delivery of micro and nano-particles 
is important in order to facilitate controlled/ delayed delivery after the drug is inserted into 
the skin (McAllister et al., 2003). Insulin delivery: Microneedles have been shown to deliver 
insulin with a significant biological effect as the blood glucose concentration was reduced by 
substantial amount using microneedles.  
7. Nanocarriers 
Nanocarriers are so small to be detected by immune system and they can deliver the drug in 
the target organ using lower drug doses in order to reduce side effects. Nanocarriers can be 
administrated into the organisms by all the routes; one of them is the dermal route. The 
nanocarriers most used and investigated for topic/transdermal drug delivery in the 
pharmaceutical field are liposomes, dendrimers, nanoparticles and nanoemulsions (Table 7). 
 
Nanocarrier Size Preparation Methods Characteristics References 
Nanoparticles  10-1000 nm In situ polymerization, 
emulsification- 
evaporation, 
emulsification-diffusion, 
emulsification-diffusion 
by solvent displacement
Solid or hollow 
particles wich have 
entraped, binded or 
encapsulated drugs. 
Domínguez-
Delgado et 
al., 2011; 
oppimath  et 
al., 2001  
Solid lipid 
nanoparticles  
50-1000 nm High-pressure 
homogenization. 
Similar to polymeric 
nanoparticles but 
made of solid lipids.
Almeida & 
Souto, 2007 
Inorganic 
nanoparticles 
<50nm Sol-gel technique Nanometric particles, 
made up of inorganic 
compounds such as 
silica, titania and 
alumina. 
García-
González, 
2009  
Liposomes  25 nm-
100 μm 
Sonication, extrusion, 
mozafari method  
Vesicles composed of 
one or more 
concentric lipid 
bilayers, separated by 
water or aqueous 
buffer compartments.
El Maghraby 
et al., 2008 
Dendrimers  3–10 nm Polymerization Macromolecular high 
branched structures. 
Menjoge et 
al., 2010 
Quantum dots  2-10nm Colloidal assembly, 
viral assembly, 
electrochemical 
assembly.
Made up of organic 
surfactants, precursors 
and solvents. 
Rzigalinski & 
Strobl, 2009 
Lipid globules 1-100 nm Emulsification 
espontaneous systems. 
Multicomponent fluid 
made of water, a 
hydrophobic liquid, 
and one or several 
surfactants resulting 
in a stable system.
Dan et al., 
2010 
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Nanocarrier Size Preparation Methods Characteristics References 
Lipid 
microcylinders  
<1 μm Self emulsification Self organizing system 
in which surfactants 
crystallize into tightly 
packed bilayers that 
spontaneously form 
cylinders  
Dodla & 
Bellamkonda
, 2008 
Lipid 
microbubbles  
<2 μm Sonication Gas filled microspheres 
stabilized by 
phospholipids, 
polymers or low 
density proteins.   
Tartis et al., 
2008 
Lipospheres  0.2-100 μm Melt method, multiple 
microemulsion, 
cosolvent method  
 
Solid lipid core 
stabilized by a 
monolayer of 
phospholipids 
molecules embedded 
in the particle surface.
Fang et al., 
2007 
Ethosomes  <400 nm Cold method, hot 
method 
Non invasive delivery 
carriers that enable 
drugs to reach the deep 
skin layers and/or the 
systemic circulation.  
Elsayed et 
al., 2006 
Aquasomes  60-300 nm Self-assembling of 
hydroxyapatite by  co-
precipitation method  
The particle core is 
composed of 
noncrystalline 
calcium phosphate or 
ceramic diamond, and 
it is covered by a 
polyhydroxyl 
oligomeric film. 
Rojas-Oviedo 
et al., 2007 
Pharmacosomes <200 nm Hand-shaking method, 
Ether-injection method 
Pure drug vesicles 
formed by 
amphiphilic drugs  
Jin et al., 
2006 
Colloidosomes  200 nm –
1.5 µm 
Self-assembly of colloidal 
particles at the interface 
of emulsion droplets  
Hollow capsules with 
elastic shells.  
Rossier-
Miranda et 
al., 2009 
Niosomes  10-1000 nm Self-assembly of 
nonionic surfactant 
Bilayered structures 
made of non-ionic 
surfactant  vesicles.  
Hong et al., 
2009 
Nanoemulsions 20-200 nm High-pressure, 
homogenization, 
microfluidization, 
phase inversion 
Temperature. 
Submicron emulsions 
o/w or w/o 
Elnaggar et 
al., 2009 
Table 7. Examples of Nanocarriers used for transdermal drug delivery 
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7.1 Liposomes 
Liposomes are hollow lipid bilayer structures that can transport hydrophilic drugs inside 
the core and hydrophobic drugs between the bilayer (Bangham, 1993). They are structures 
made of cholesterol and phospholipids. They can have different properties depending on 
the excipients included and the process of their elaboration. The nature of liposomes makes 
them one of the best alternatives for drug delivery because they are non-toxic and remain 
inside the bloodstream for a long time. Liposomes can be surface-charged as neutral, 
negative or positive, depending on the functional groups and pH medium. Liposomes can 
encapsulate both lipophilic and hydrophilic drugs in a stable manner, depending on the 
polymer added to the surface (Rodriguez-Justo & Morae et al., 2011). There are small 
unilamellar vesicles (25 nm to 100nm), medium-sized unilamellar vesicles (100 nm and 
500nm), large unilamellar vesicles, giant unilamellar vesicles, oligolamellar vesicles, large 
multilamellar vesicles and multivesicular vesicles (500 nm to microns). The thickness of the 
membrane measures approximately 5 to 6 nm. These shapes and sizes depend of the 
preparation technique, the lipids used and process variables. Depending on these 
parameters, the behavior both in vivo and in vitro can change and opsonization processes, 
leakage profiles, disposition in the body and shelf life are different due to the type of 
liposome (Rodriguez-Justo & Morae et al., 2011).  
Liposomes preparation techniques follow three basic steps with particular features 
depending on safety, potential scale up and simplicity: 1) Lipid must be hydrated, 2) 
Liposomes have to be sized and 3) Nonencapsulated drug has to be removed. The degree 
of transdermal drug penetration is affected by the lamellarity, lipid composition, charge 
on the liposomal surface, mode of application and the total lipid concentrations (Cevc & 
Blume, 1992). Some examples of drugs delivered throughout the skin by using liposomes 
are melatonin (Dubey et al., 2007b), indinavir (Dubey et al., 2010), amphotericin B 
(Manosroi et al., 2004), methotrexate (Dubey et al., 2007a), ketoprofen (Maestrelli et al., 
2005), estradiol (Essa et al., 2004), clindamicyn hydrochloride and lignocaine (Sharma et 
al., 1994).  
7.2 Dendrimers 
Dendrimers are monodisperse populations that are structurally and chemically uniform. 
They allow conjugation with numerous functional groups due to the nature of their 
branches. The amount of branches increases exponentially and dendrimers growth is 
typically about 1 nm per generation (Svenson & Tomalia, 2005). The dendrimers 
classification is based on the number of generations. After the creation of a core, the 
stepwise synthesis is called first generation; after that, every stepwise addition of monomers 
creates the next generation. This approach allows an iterative synthesis, providing the 
ability to control both molecular weight and architecture. 
The kind of polymer chosen to construct the dendrimer by polimerization is very important 
with regard to the final architecture and features. In addition, the use of branched 
monomers has the peculiarity of providing tailored loci for site-specific molecular 
recognition and encapsulation. Notably, 3D and fractal architecture, as well as the 
peripheral functional groups, provide dendrimers with important characteristic physical 
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and chemical properties. In comparison with linear polymers, dendritic structures have 
“dendritic voids” that give these molecules important and useful features. These spaces 
inside dendrimers can mimic the molecular recognition performed by natural proteins. 
Furthermore, dendrimers have a high surface-charge density due to ionizable groups that 
help them to attach drugs by electrostatic forces, regardless of the stoichimetry. This 
dendrimer-drug association provides drugs with better solubility, increasing their transport 
through biological membranes and sometimes increasing drug stability. The number of 
molecules that can be incorporated into dendrimers is related to the number of surface 
functional groups; therefore, later-generation dendrimers are more easily incorporated into 
dendritic structure. However, not all the functional groups are available for interaction due 
to steric volume, molecule rotation or stereochemistry effects. Dendrimers can have positive 
and negative charges, which allows them to complex different types of drugs (Kabanov et 
al., 1998). The main problems with this kind of transdermal carrier are poor biodegradation 
and inherent cytotoxicity (Parekh, 2007). In order to reduce their toxicity, dendrimers have 
been linked to peptides and which are formed from amino acids linked via peptide-amide 
bonds to the branches of dendrimers in the core or on the surface. When they are bio-
transformed, dendrimer-peptide systems produce amino-acid derivatives. Finally, the 
synthesis of these structures is less expensive and purification does not present any 
difficulty (Niederhafner et al., 2005). Due to their form and size, these molecules can carry 
drugs, imaging agents, etc. Dendrimers interact with lipids present in membranes, and they 
show better permeation in cell cultures and intestinal membranes (Cheng et al., 2008). 
Dendrimers also act like solubility enhancers, increasing the permeation of lipophilic drugs; 
nevertheless, they are not good carriers for and hydrophilic drugs. 
7.3 Nanoparticles 
Nanoparticles are smaller than 1,000 nm. Nowadays, it is possible to insert many types of 
materials such as drugs, proteins, peptides, DNA, etc. into the nanoparticles. They are 
constructed from materials designed to resist pH, temperature, enzymatic attack, or other 
problems (Huang L. et al., 2010; Wei et al., 2010). The nanoparticle technology can be 
divided into three stages: first generation (involves those nanoparticles that had only one 
component in their structure and these delivery systems are able to transport drugs in the 
blood until they reach the target), second generation (implies nanoparticles made of one 
main component and additional substances and these complexes are able to cross barriers 
and reach difficult targets such as the brain) and third generation is represented by 
nanoparticles that can be made of nanoparticles with one main component combined with a 
second component to reach a specific target (Cui et al., 2005; Herffernan & Murthy, 2005). 
Moreover, nanoparticles can be classified as nanospheres or nanocapsules (Figure 4). 
Nanospheres are solid-core structures and nanocapsules are hollow-core structures (Yoo et 
al., 2005). Nanoparticles can be composed of polymers, lipids, polysaccharides and proteins 
(Goswami et al., 2010; Li et al., 2009). Nanoparticles preparation techniques are based on 
their physicochemical properties. They are made by emulsification-diffusion by  
solvent displacement, emulsification-polymerization, in situ-polymerization, gelation, 
nanoprecipitation, solvent evaporation/extraction, inverse salting out, dispersion 
polymerization and other derived from these one. 
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a)                                             b) 
Fig. 4. a) Nanospheres and b) nanocapsules. 
7.4 Nanoemulsions 
Nanoemulsion are isotropic dispersed systems of two non miscible liquids, normally 
consisting of an oily system dispersed in an aqueous system (o/w nanoemulsion), or an 
aqueous system dispersed in an oily system but forming droplets or other oily phases of 
nanometric sizes (100 nm). They can be stable (methastable) for long times due to the 
extremely small sizes and the use of adequate surfactants. Nanoemulsions can use 
hydrophobic and hydrophilic drugs because it is possible to make both w/o or o/w  
nanoemulsions (Sonneville-Aubrun, et al. 2004). They are non-toxic and non-irritant systems 
and they can be used for skin or mucous membranes, parenteral and non parenteral 
administration in general and they have been used in the cosmetic field. Nanoemulsions can 
be prepared by three methods mainly: high-pressure homogenization, microfluidization and 
phase inversion temperature. Transdermal delivery using nanoemulsions has been reduced 
due to the stability problems inherent to this dosage form. Some examples of drugs using 
nanoemulsions to transdermal drug delivery are gamma tocopherol, caffeine, plasmid DNA, 
aspirin, methyl salicylate, insulin and nimesulide (Shakeel & Ramadan, 2010).  
8. Conclusions 
Transdermal drug delivery has several potential advantages over other parenteral delivery 
methods. Apart from the convenience and noninvasiveness, the skin also provides a 
“reservoir” that sustains delivery over a period of days. Furthermore, it offers multiple sites 
to avoid local irritation and toxicity, yet it can also offer the option to concentrate drugs at 
local areas to avoid undesirable systemic effects. However, at present, the clinical use of 
transdermal delivery is limited by the fact that very few drugs can be delivered 
transdermally at a viable rate. This difficulty is because the skin forms an efficient barrier for 
most molecules, and few noninvasive methods are known to significantly enhance the 
penetration of this barrier.  
In order to increase the range of drugs available for transdermal delivery the use of  
chemical and physical enhancement techniques have been developed in an attempt to 
compromise skin barrier function in a reversible manner without concomitant skin 
irritation. Recently, several alternative physical methods have emerged to transiently break 
the stratum corneum barrier and also the use of chemical enhancers continues expanding. 
The projectile methods use propelled microparticles and nanoparticles to penetrate the skin 
barrier. Microneedle arrays are inserted through the skin to create pores. “Microporation” 
creates arrays of pores in the skin by heat and radio frequency ablation. Also, ultrasound 
has been employed to disrupt the skin barrier. All these methods have their own advantages 
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and drawbacks, but a reality is that new developments are expected in the future to make 
these methods even more versatile. 
9. Acknowledgments 
José Juan Escobar-Chávez wishes to acknowledge PAPIIT TA 200312 y PAPIIT IN 209709-3. 
The authors report no conflict of interests. 
10. References 
Aditya NP, Patankar S, Madhusudhan B, Murthy RSR & Souto EB. (2010). Arthemeter-
loaded lipid nanoparticles produced by modified thin-film hydration: 
Pharmacokinetics, toxicological and in vivo anti-malarial activity. European Journal 
of Pharmaceutical Sciences, Vol. 40, pp.448-455, ISSN 0928-0987.  
Agyralides, GG.; Dallas PP.; Rekkas, DM. (2004). Development and in vitro evaluation of 
furosemide transdermal formulations using experimental design techniques. 
International Journal of Pharmaceutics, Vol. 281, No.1-2, (August 2004), pp. 35-43, 
ISSN 0378-5173. 
Akinbo, SR.; Aiyejusunle, CB.; Akinyemi, OA.; Adesegun, SA, & Danesi MA. (2007). 
Comparison of the therapeutic efficacy of phonophoresis and iontophoresis using 
dexamethasone sodium phosphate in the management of patients with knee 
ostheoarthritis. Nigerian Postgraduate Medical Journal; Vol. 14, No. 3, (September 
2007), pp.190-94, ISSN 1117-1936. 
Allan, G. Azone®. (1995). In: Percutaneous Penetration Enhancers, Smith EW, Maibach HI, Eds, 
pp. 129-3, Florida, Boca Raton.  
Almeida AJ, Souto E. (2007). Solid lipid nanoparticles as a drug delivery system for peptides 
and proteins. Advanced Drug Delivery Reviews, vol. 59 pp.478-490, ISSN 0169-409X.  
Al-Qallaf B, Das DB &  Davidson A. (2009a). Transdermal drug delivery by coated 
microneedles: Geometry effects on drug concentration in blood. Asia-Pacific Journal 
of Chemical Engineering. Vol. 4, No. 6, (November/December 2009), pp. 845-857, 
ISSN 1932-2143.  
Al-Qallaf B, Das DB. (2009b). Optimizing microneedle arrays to increase skin permeability 
for transdermal drug delivery. Annals of the New York Academy of Sciences. 1161: 83-
94. 
Alvarez-Roman R, Naik A, Kalia YN, Guy RH & Fessi H. (2004). Skin penetration and 
distribution of polymeric nanoparticles. Journal of Controlled Release, Vol. 99, pp.53-
62, ISSN 0168-3659.   
Alvarez-Román, R.; Merino, G.; Kalia, YN.; Naik, A, Guy & RH. (2003). Skin permeability 
enhancement by low frequency sonophoresis: Lipid extraction and transport 
pathways. Journal of Pharmaceutical Sciences, Vol. 92, No. 6, (June 2003), pp. 1138-46, 
ISSN 0022-3549. 
Amnuaikit, C.; Ikeuchi, I.; Ogawara, K.; Higaki, K. & Kimura, T. (2005). Skin permeation of 
propranolol from polymeric film containing terpene enhancers for transdermal use. 
International Journal of Pharmaceutics, Vol. 289, No. 1-2, (January 2005), pp.167-78, 
ISSN 0378-5173. 
Amrish, C. & Kumar SP. (2009). Transdermal delivery of ketorolac. Yakugaku Zasshi, Vol.129, 
No.3, (March 2009), pp. 373-9, ISSN 1347-5231. 
www.intechopen.com
 Chemical and Physical Enhancers for Transdermal Drug Delivery 
 
421 
Aoi, A.; Watanabe, Y, Mori S, et al. (2007). Herpes simplex virus thymidine kinase mediated 
suicide gene therapy using nano/microbubbles and ultrasound. Ultrasound In 
Medicine & Biology, Vol. 34, No. 39, (March 2008) pp. 425-434, ISSN 0301-5629. 
Arias JL, López-Viota M, López-Viota J & Delgado AV. (2009). Development of 
iron/ethylcellulose (core/shell) nanoparticles loaded with diclofenac sodium for 
arthritis treatment. International Journal of Pharmaceutics. Vol.382, pp.270-276, ISSN: 
0378-5173. 
Babu, RJ.; Dhanasekaran, M.; Vaithiyalingam, SR.; Singh, PN. & Pandit, JK. (2008). 
Cardiovascular effects of transdermally delivered bupranolol in rabbits: effect of 
chemical penetration enhancers. Life Science, Vol. 82, No. 5-6, (January 2008), pp. 
273-8, ISSN 0024-3205. 
Balaguer-Fernández, C.; Padula, C.; Femenía-Font, A.; Merino, V.; Santi, P. & López-
Castellano A. (2010). Development and evaluation of occlusive systems employing 
polyvinyl alcohol for transdermal delivery of sumatriptan succinate. Drug Delivery, 
Vol. 17, No. 2, (February 2010), pp. 83-91, ISSN 1521-0464. 
Ball C, Thomson KR, Kavnoudias H. Irreversible Electroporation: A New Challenge in "Out 
of Operating Theater" Anesthesia. Anesthesia Analgesia, Vol. 110, No. 5, (May 
2010), pp. 1305-9, ISSN 1526-7598. 
Banga AK, Bose S & Ghosh TK. (1999). Iontophoresis and electroporation: comparisons and 
contrasts. International Journal of Pharmaceutics. Vol.179 pp. 1–19, ISSN: 0378-5173. 
Bangham AD. (1993). Liposomes: the Babraham connection. Chemistry and Physics of Lipids. 
Vol. 64, pp.275-285, ISSN 0009-3084. 
Barry, BW & Williams, AC. (1991). Terpenes and the lipid-protein-partititioning theory of 
skin penetration enhancement. Pharmaceutical Research, Vol. 8, No. 1, (January 
1991), pp. 17–24, ISSN 1573-904X.   
Barry, BW.  (1983). Dermatological Formulations: Percutaneous Absorption, Marcel Dekker, ISBN 
0824717295, New York. 
Barry, BW. (2001). Novel mechanisms and devices to enable successful transdermal drug 
delivery. European Journal of Pharmaceutical Sciences, Vol. 14, No. 2, (September 
2001), pp. 101–4, ISSN 0928-0987. 
Becker SM, Kuznetsov AV. (2007). Numerical assessment of thermal response associated 
with in vivo skin electroporation: the importance of the composite skin model. 
Journal of Biomechanical Engineering, Vol. 129, No. 3, (June 2007), pp.330-40, ISSN 
0148-0731. 
Boucaud, A.; Machet, L.; Arbeille, B.; et al. (2001). In vitro study of low-frequency 
ultrasound-enhanced transdermal transport of fentanyl and caffeine across human 
and hairless rat skin. International Journal of Pharmaceutics, Vol. 228, No. 1-2, 
(October 2001), pp. 69-77, ISSN 0378-5173. 
Bounoure, F.; Lahiani-Skiba, M.; Besnard, M.; Arnaud, P.; Mallet, E. & Skiba M. (2008). Effect 
of iontophoresis and penetration enhancers on transdermal absorption of 
metopimazine. Journal of Dermatological Science, Vol. 52, No. 3, (December 2008), pp. 
170-7, ISSN 0923-1811. 
Byl, NN.; McKenzie, A.; Halliday, B.; Wong, T.& O'Connell J. (1993) The effects of 
phonophoresis with corticosteroids controlled pilots study. Journal of Orthopaedic 
Sports Physical Therapy, Vol. 18, No. 5, (November 1993), pp. 590-600, ISSN 0190-
6011. 
www.intechopen.com
 Pharmacology 
 
422 
Cabak, A.; Maczewska, M.; Lyp, M.; Dobosz, J. & Gasiorowska U. (2005). The effectiveness 
of phonophoresis with ketoprofen in the treatment of epocondylopathy. Ortopedia, 
Traumatologia, Rehabilitacja; Vol. 37, No. 6, (December 2005), pp. 660-65. ISSN 1509-
3492. 
Cancel, LM.; Tarbell, JM. & Ben-Jebria A. (2004). Fluorescein permeability and electrical 
resistance of human skin during low frequency ultrasound application. Journal of 
Pharmacuy and Pharmacology, Vol. 56, No. 9, (September 2004), pp. 1109-18, ISSN 
0022-3573. 
Cázares-Delgadillo, J.; Naik, A.; Kalia, YN.; Quintanar-Guerrero, D. & Ganem-Quintanar A. 
(2005) Skin permeation enhancement by sucrose esters: A pH-dpendent 
phenomenon. International Journal of Pharmaceutics, Vol. 297, No. 1-2, (June 2005), 
pp. 204-212, ISSN 0378-5173. 
Cevc G, Blume G. (1992). Lipid vesicles penetrate into intact skin owing to the transdermal 
osmotic gradients and hydration force. Biochimica et Biophysica Acta. Vol. 1104, 
pp. 226-232.  
Chabri F, Bouris K, Jones T, Barrow D, Hann A, Allender C, Brain K & Birchall J. (2009). 
Microfabricated silicon microneedles for nonviral cutaneous gene delivery. The 
British Journal of Dermatology, Vol. 150, No. 5, pp. 869–77, ISSN: 0007-0963. 
Chen B, Wei J, Tay FE, Wong YT & Iliescu C. (2008). Silicon microneedle array with 
biodegradable tips for transdermal drug delivery. Microsystem Technologies. Vol. 14, 
No. 7, pp. 1015-19, ISSN: 0946-7076. 
Chen T, D’Addio SM, Kennedy MT, Swietlow A, Kevrekidis IG & Panagiotopoulos AZ. 
(2009). Protected Peptide Nanoparticles: Experiments and Brownian Dynamics 
Simulations of the Energetics of Assembly. Nano Letters, Vol. 9, pp. 2218-2222, 
ISSN: 1530-6984.  
Cheng Y, Xu Z, Ma M & Xu T. (2008). Dendrimers as drug carriers: Applications in different 
routes of drug administration. Journal of Pharmaceutical Sciences, Vol. 97, pp.123-143, 
ISSN 0022-3549.  
Clarke, L.; Edwards, A.; Graham, E. (2004) Acoustic streaming: an in vitro study. Ultrasound 
In Medicine & Biology, Vol. 30, No. 4, (April 2004), pp. 559–62, ISSN 0301-5629. 
Cui Z, Han S, Padinjarae D & Huang L. (2005). Immunsotimulation mechanism of LPD 
nanoparticles as a vaccine carrier. Molecular Pharmacology, Vol. 2, pp. 22-28, ISSN: 
0026-895X.  
Dan Y, Liu H, Gao W & Chen S. (2010). Activities of essential oils from Asarum 
heterotropoides var. mandshuricum against five phytopathogens. Crop Protection. 
Vol. 29, No. 295-299. ISSN: 0261-2194. 
Davis SP, Martanto W, Allen MG & Prausnitz MR. (2005). Hollow metal microneedles for 
insulin delivery to diabetic rats. IEEE T. BioMedical Engineering, Vol. 52, No 5, pp. 
909-15, ISSN: 0018-9294. 
Delgado-Charro MB, Guy RH. (1994). Characterization of convective solvent flow during 
iontophoresis. Pharmaceutical Research, Vol. 11, No. 7, (July 1994), pp. 29-35, ISSN 
0724-8741. 
Díaz-Torres, R. (2010). Transdermal nanocarriers. In: Current Technologies to Increase the 
Transdermal Delivery of Drugs, José Juan Escobar-Chávez/Virginia Merino (Eds.), 
pp., 120-40, Bentham Science Publishers, ISBN 978-1-60805-191-5, The Netherlands. 
www.intechopen.com
 Chemical and Physical Enhancers for Transdermal Drug Delivery 
 
423 
Dodla MC, Bellamkonda RV. (2008). Differences between the effect of anisotropic and 
isotropic laminin and nerve growth factor presenting scaffolds on nerve 
regeneration across long peripheral nerve gaps. Biomaterials. Vol. 29, pp.33-46, 
ISSN: 0142-9612. 
Domínguez-Delgado C. L., Rodríguez-Cruz I. M. & López-Cervantes M. (2010). Chapter 1: 
The skin a valuable route for administration of drugs. In: José Juan Escobar-Chávez 
(Ed), Current Technologies To Increase The Transdermal Delivery Of Drugs. Bentham 
Science Publishers Ltd. ISBN: 978-1-60805-191-5, Bussum, The Netherlands.  
Domínguez-Delgado C. L., Rodríguez-Cruz I. M., Escobar-Chávez J. J., Calderón-Lojero I. 
O., Quintanar-Guerrero David & Ganem-Quintanar Adriana. (2011). Triclosan 
nanoparticles as a novel option for acne treatment. European Journal of Pharmaceutics 
and Biopharmaceutics. IN PRESS, ISSN: 0928-0987. 
Donnelly RF, Morrow DI, McCarron PA, Woolfson AD, Morrissey A, Juzenas P, Juzeniene 
A, Lani, V, McCarthy HO & Moan J. (2009). Microneedle arrays permit enhanced 
intradermal delivery of a preformed photosensitizer. Photochemistry and 
Photobiology. Vol. 85, pp. 195-204, ISSN 1751-1097. 
Dubey V, Mishra D & Jain NK. (2007b). Melatonin loaded ethanolic liposomes: 
Physicochemical characterization and enhanced transdermal delivery. European 
Journal of Pharmaceutics and Biopharmaceutics. Vol. 67, pp. 398-405, ISSN: 0928-0987.  
Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK & Jain NK. (2007a). Dermal and 
transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. Journal of 
Controlled Release, Vol. 123, pp.148-154, ISSN 0168-3659.  
Dubey V, Mishra D, Nahar M, Jain V & Jain NK. (2010). Enhanced transdermal delivery of 
an anti-HIV agent via ethanolic liposomes. Nanomedicine: Nanotechnology, Biology 
and Medicine. Vol. 6. No. 4, (2010 August), pp. 590-6, ISSN: 1549-9634. 
El Maghraby GM, Barry BW & Williams AC. (2008). Liposomes and skin: From drug 
delivery to model membranes. European Journal of Pharmaceutical Sciences, Vol. 34, 
pp.203-222, ISSN 0928-0987.  
El-Kamel, AH.; Al-Fagih, IM. & Alsarra IA. (2008). Effect of sonophoresis and chemical 
enhancers on testosterone transdermal delivery from solid lipid microparticles:an 
in vitro study, Current Drug Delivery, Vol. 5, No. 1, (January 2008), pp. 20-26, 
 ISSN 1567-2018. 
Elnaggar YSR, El-Massik MA & Abdallah OY. (2009). Self-nanoemulsifying drug delivery 
systems of tamoxifen citrate: Design and optimization. International Journal of 
Pharmaceutics. Vol.380, pp.133-141, ISSN: 0378-5173. 
Elsayed MMA, Abdallah OY, Naggar VF & Khalafallah NM. (2006). Deformable liposomes 
and ethosomes: Mechanism of enhanced skin delivery. International Journal of 
Pharmaceutics. Vol. 322, pp. 60-66, ISSN: 0378-5173.  
Escobar-Chávez JJ, Bonilla-Martínez D, Villegas-González M.A. (2010b). Sonophoresis: A 
valuable physical enhancer to increase transdermal drug delivery. In: Current 
Technologies to Increase the Transdermal Delivery of Drugs, José Juan Escobar-
Chávez/Virginia Merino (Eds.), pp. 53-76, Bentham Science Publishers, ISBN 978-1-
60805-191-5, The Netherlands. 
Escobar-Chávez JJ, Melgoza-Contreras LM, López-Cervantes M, et al. (2009c). The tape 
stripping technique as a valuable tool for evaluating topical applied compounds. 
In: Frontiers in Drug Design & Discovery, Gary W. Caldwell /Atta-ur-Rahman / Z. 
www.intechopen.com
 Pharmacology 
 
424 
Yan / M. Iqbal Choudhary (Eds.) Vol. 4, pp. 189-227, Bentham Science Publishers, 
eISBN 978-1-60805-202-8. 
Escobar-Chávez JJ, Merino-Sanjuán V, López-Cervantes M, et al. (2009d). The use of 
iontophoresis in the administration of nicotine and new non nicotine drugs 
through the skin for smoking cessation. Current Drug Discovery Technologies, Vol. 6, 
No. 3, (September 2009), 171-185, ISSN 1570-1638. 
Escobar-Chávez JJ, Quintanar-Guerrero D, and Ganem-Quintanar A. (2005). In vivo skin 
permeation of sodium naproxen formulated in PF-127 gels: Effect of Azone® and 
Transcutol®. Drug Development and Industrial  Pharmacy; Vol. 31 No.  4-5, (May 
2005), pp.447-54, ISSN 0363-9045. 
Escobar-Chávez, JJ. & Merino, V. 2010a. Current Technologies to increase the Transdermal 
Delivery of Drugs,  Bentham Science Publishers, ISBN: 978-1-60805-191-5, Bussum, 
The Netherlands.  
Escobar-Chávez, JJ.; Bonilla-Martínez, D.; Villegas-González, A.; Rodríguez-Cruz, IM.; 
Domínguez-Delgado, CL. (2009a). The use of sonophoresis in the administration of 
drugs through the skin. Journal of Pharmacy and Pharmaceutical Sciences, Vol. 12, No. 
1, (April 2009), pp. 88-115,  ISSN: 1482-1826. 
Escobar-Chávez, JJ.; Bonilla-Martínez, D.; Villegas-González, A.; Revilla-Vazquez, AL. 
(2009b). The electroporation as an efficient physical enhancer for transdermal drug 
delivery. Journal of Clinical Pharmacology, Vol. 49, No. 11, (August 2008), pp. 1262-
83, ISSN: 0091-2700. 
Escobar-Chávez, JJ.; López-Cervantes, M.; Naïk, A.; et al. (2006). Applications of the 
thermoreversible Pluronic F-127 gels in pharmaceutical formulations. Journal of 
Pharmacy and Pharmceutical Sciences; Vol. 9, No. 3, (November 2006), pp. 339-58, 
ISSN 1482-1826. 
Escobar-Chávez, JJ.; Merino, V.; Díez-Sales, O.; Nácher-Alonso, A.; Ganem-Quintanar, A.; 
Herráez, M.; Merino-Sanjuán, M. (2008). The tape-stripping technique as a method 
for drug quntification in the skin. Journal of Pharmacy and Pharmaceutical Sciences, 
Vol. 11, No. 1, (March 2008):104-30, ISSN 1482-1826. 
Escobar-Chávez, JJ.; Merino, V.; Díez-Sales, O.; Nácher-Alonso, A.; Ganem-Quintanar, A.; 
Herráez, M.; Merino-Sanjuán, M. (2011). Transdermal nortriptyline hydrocloride 
patch formulated within a chitosan matrix intended to be used for smoking 
cessation. Pharmaceutical Development Technology, Vol. 16, No. 2, (February 2010), 
pp. 162-9, ISSN 1083-7450 
Escribano, E.; Calpena, AC.; Queralt, J.; Obach, R.; Doménech J. (2003). Assessment of 
diclofenac permeation with different formulations: anti-inflammatory study of a 
selected formula, European Journal of Pharmaceutical Sciences, Vol. 19, No. 4, (July 
2003),  pp. 203-210, ISSN 0928-0987. 
Essa EA, Bonner MC & Barry BW. (2004). Electrically assisted skin delivery of liposomal 
estradiol; phospholipid as damage retardant. Journal of Controlled Release, Vol. 95, 
pp.535-546, ISSN 0168-3659.   
Fang J, Hung C, Liao M & Chien C. (2007). A study of the formulation design of acoustically 
active lipospheres as carriers for drug delivery. European Journal of Pharmaceutics 
and Biopharmaceutics. Vol. 67, pp. 67-75.  
www.intechopen.com
 Chemical and Physical Enhancers for Transdermal Drug Delivery 
 
425 
Fang JY, Lin HH, Chen HI, Tsai YH. (1998). Development and evaluation on transdermal 
delivery of enoxacin via chemical enhancers and physical iontophoresis. Journal of 
Controlled Release, Vol. 54, No. (August 1998), pp. 293-304, ISSN 0168-3659.  
Fang, JY.; Fang, CL.; Huang, YB.; Tsai, YH. (2002). Transdermal iontophoresis of sodium 
nonivamide acetate. V. Combined effect of pre-treatment by penetration enhancers. 
International Journal of Pharmaceutics, Vol. 235, No. 1-2, (March 2002), 95-105, ISSN 
0378-5173. 
Fang, JY.; Leu, YL.; Wang, YY.; Tsai, YH. (2002). In vitro topical application and in vivo 
pharmacodynamic evaluation of nonivamide hydrogels using Wistar rat as an 
animal model. European Journal of Pharmaceutical Sciences, Vol. 15, No. 5, (June 2002), 
pp. 417-23, ISSN 0928-0987. 
García-González CA, Sampaio da Sousa AR, Argemí A, López Periago A, Saurina J, Duarte 
CM & Domingo C. (2009). Production of hybrid lipid-based particles loaded with 
inorganic nanoparticles and active compounds for prolonged topical release. 
International Journal of Pharmaceutics. Vol.382  No.1-2 (December 2009), pp.296-304. 
ISSN: 0378-5173. 
Gardeniers HJ, Luttge R, Berenschot EJ, de Boer MJ, Yeshurun SY, Hefetz M, van't Oever R 
& van den Berg A. (2003). Silicon micromachined hollow microneedles for 
transdermal liquid transport. Journal of Medieval and Early Modern Studies. Vol. 
12, pp 855-62. 
Gill SH, Prausnitz RM. (2006). Coated microneedles for transdermal drug delivery. Journal of 
Controlled Release, Vol. 117, pp.227-37, ISSN 0168-3659.  
Goswami S, Bajpai J & Bajpai AK. (2010). Designing Gelatin Nanocarriers as a Swellable 
System for Controlled Release of Insulin: An In-Vitro Kinetic Study. Journal of 
Macromolecular Science. Vol. 47, pp.119-130, ISSN 1060-1325.  
Griffin,  JE. & Touchstone, JC. (1972). Effects of ultrasound frequency on cortisone into 
swine tissue. American Journal of Physcal Medicine, Vol. 51, No. 2, (April 1972), pp. 
62-78, ISSN 0002-9491.  
Güngör, S.; Bektaş, A.; Alp, FI.; Uydeş-Doğan, BS.; Ozdemir, O.; Araman, A.; Ozsoy, Y. 
(2008). Matrix-type transdermal patches of verapamil hydrochloride: in vitro 
permeation studies through excised rat skin and pharmacodynamic evaluation in 
rats. Pharmaceutical Development Technology, Vol. 13, No. 4, pp. 283-9, ISSN 1083-
7450. 
Guy RH, Kalia YN, Delgado-Charro MB, Merino V, Lopez A, Marro D. (2000). 
Iontophoresis: electrorepulsion and electroosmosis. Journal of Controlled Release, 
Vol. 64, No. 1-3, (February 2000), pp. 129-32, ISSN 0168-3659. 
Hadgraft, J. &  Lane, ME. (2005). Skin permeation: The years of enlightenment. International 
Journal of Pharmaceutics, Vol. 305, No. 1-2, (November 2005), pp. 2–12, ISSN 0378-
5173. 
Hadgraft, J.; Walters, KA. & Wotton, PK. (1985). Facilitated transport of sodium salicylate 
across an artificial lipid membrane by azone. Journal of Pharmacy and Pharmacology, 
Vol. 37, No. 10, (October 1985), pp. 725-727, ISSN 0022-3573. 
Haq MI, Smith E, John DN, Kalavala M, Edwards C, Anstey A, Morrissey A & Birchall JC. 
(2009). Clinical administration of microneedles: skin puncture, pain and sensation. 
Biomedical Microdevices. Vol. 11, pp 35–47, ISSN: 1387-2176. 
www.intechopen.com
 Pharmacology 
 
426 
Hathout, RM.; Woodman, TJ.; Mansour, S.; Mortada, ND.; Geneidi, AS.; Guy, RH. (2010). 
Microemulsion formulations for the transdermal delivery of testosterone. European 
Journal of Pharmaceutical Sciences, Vol. 40, No. 3, (June 2010), pp. 188-96, ISSN 0928-
0987. 
Hehn, B. & Moll, F. (1996). Phonophoretic permeation of procaine hydrochloride through 
and MDCK cell monolayer. Pharmazie; Vol. 51, No. 5, (May 1996), pp. 341-5, ISSN 
0031-7144. 
Heller, R.; Jaroszeski, R.;  Glass, LF.; et al. (1996). Phase I / II Trial for the treatment of 
cutaneous and subcutaneous tumor using electrochemotherapy, Cancer, Vol. 77, 
No. 5, (March 1996), pp. 964–971, ISNN 1097-0142. 
Henry S, McAllister V D, Mark GA & Prausnitz RM. (1998). Microfabricated microneedles: 
A novel approach to transdermal drug delivery. Journal of Pharmaceutical Sciences, 
Vol. 87, pp.922-25, ISSN 0022-3549. 
Herffernan M, Murthy N. (2005). Polyketal nanoparticles: A new pH-sensitive 
biodegradable drug delivery vehicle. Bioconjugate Chemistry. Vol. 16, pp.1340-1342,   
Hippius, M.; Uhlemann, C.; Smolenski, U.; et al. (1998). In vitro investigations of drug 
release and penetration enhancing effect of ultrasound on transmembrane 
transport of flufenamic acid. International Journal of Clinical Pharmacoloy & 
Therapeutics, Vol. 36, No. 2, (September 1998), pp. 107 11, ISSN 0946-1965.  
Hong M, Zhu S, Jiang Y, Tang G & Pei Y. (2009). Efficient tumor targeting of 
hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. 
Journal of Controlled Release, Vol. 133, pp.96-102, ISSN 0168-3659.   
Huang X, Du Y, Yuan H & Hu F. (2009). Preparation and pharmacodynamics of low-
molecular-weight chitosan nanoparticles containing insulin. Carbohydrate 
Polymers. Vol. 76, pp. 368-373, ISSN: 0144-8617 
Huang, JF.; Sung, KC.; Wang, JJ.; Lin, YH.; Fang, JY. (2005). The effects of electrically assisted 
methods on transdermal delivery of nalbuphine benzoate and sebacoyl 
dinalbuphine ester from solutions and hydrogels. International Journal of 
Pharmaceutics,Vol. 297, No. 1-2, (April 2005), pp. 162–171, ISSN 0378-5173. 
Jin Y, Tong L, Ai P, Li M & Hou X. (2006). Self-assembled drug delivery systems: 1. 
Properties and in vitro/in vivo behavior of acyclovir self-assembled nanoparticles 
(SAN). International Journal of Pharmaceutics. Vol.309, pp.199-207, ISSN: 0378-5173. 
Johnson S, Trejo J, Veisi M, Willhite GP, Liang JT & Berkland C. (2010). Effects of Divalent 
Cations, Seawater, and Formation Brine on Positively Charged 
Polyethylenimine/Dextran Sulfate/ Chromium(III) Polyelectrolyte Complexes and 
Partially Hydrolyzed Polyacrylamide/Chromium(III) Gelation. Journal of Applied 
Polymer Science. Vol. 115, pp.1008-1014, ISSN 1097-4628.   
Joshi M, Patravale V. (2008). Nanostructured lipid carrier (NLC) based gel of celecoxib. 
International Journal of Pharmaceutics. Vol.346, pp.124-132, ISSN: 0378-5173. 
Kabanov, V.A.; Zezin, A.B.; Rogacheva, V.B.; Gulyaeva, Z.G.; Zansochova, M.F.; Joosten, 
J.G.H. & Brackman, J. (1998). Polyelectrolyte behavior of astramol 
poly(propyleneimine) dendrimers. Macromolecules. Vol 31, pp.142-5144, ISSN 0024-
9297. 
Khaibullina, A.; Jang, BS.; Sun, H.; et al. (2008). Pulsed high intensity focused ultrasound 
enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor 
www.intechopen.com
 Chemical and Physical Enhancers for Transdermal Drug Delivery 
 
427 
in nude mice. Journal of Nuclear Medicine, Vol. 49, No. 2, (February 2008), pp. 295-
302, ISSN 0161-5505. 
Kigasawa, K.; Kajimoto, K.; Watanabe, M.; Kanamura, K.; Saito, A.; Kogure, K. (2009). In 
vivo transdermal delivery of diclofenac by ion-exchange iontophoresis with 
geraniol. Biological & Pharmaceutical Bullettin, Vol. 32, No. 4, (April 2009), pp. 684-7, 
ISSN 0918-6158. 
Kim, TY.; Jung, DI.; Kim, YI.; Yang, JH.; Shin, SC. (2007). Anesthetic effects of lidocaine 
hydrochloride gel using low frequency ultrasound of 0.5MHz. Journal of Pharmacy 
& Pharmaceutical Sciences, Vol, 10, No. 1, (February 2007), pp. 1-8, ISSN 1482-1826. 
Kushner IV, J.; Blankschtein, D. & Langer, R. (2008). Heterogeneity in skin treated with low-
frequency ultrasound. Journal of Pharmaceutical Sciences, Vol. 97, No. 10, (October 
2008), pp. 4119–28, ISSN 0022-3549. 
Kwon S.-Y., (2006). Acne Treatment by a Dissolvable Microneedle Patch, Proceedings of  
Controlled Release Society 33st Annual Meeting; #115. 
Larkin, JO.; Casey, GD.; Tangney, M.; et al. (2008). Effective tumor treatment using 
optimized ultrasound mediated delivery of bleomycin. Ultrasound In Medicine & 
Biology, Vol.34, No. 3, (March 2008), pp. 406-13, ISSN 0301-5629. 
Lboutounne H, Chaulet J, Ploton C, Falson F & Pirot F. (2002). Sustained ex vivo skin 
antiseptic activity of chlorhexidine in poly(ε-caprolactone) nanocapsule 
encapsulated form and as a digluconate. Journal of Controlled Release, Vol. 82, 
pp.319-334, ISSN 0168-3659.   
Leboulanger B, Aubry JM, Bondolfi G, Guy RH, Delgado-Charro MB. (2004). Lithium 
monitoring by reverse iontophoresisinvivo. Clinical Chemistry, Vol. 50, No. 11, 
(November 2004), pp. 2091-100, ISSN 1530-8561. 
Lee P, Peng S, Su C, Mi F, Chen H, Wei M, Lin, H & Sung H. (2008). The use of 
biodegradable polymeric nanoparticles in combination with a low-pressure gene 
gun for transdermal DNA delivery. Biomaterials. Vol.29, No. 6, (February 2008) pp. 
742-751, ISSN: 0142-9612.  
Lee WJ, Park J & Prausnitz RM. (2007). Dissolving microneedles for transdermal drug 
delivery. Biomaterials.  Vol. 29, pp. 2113-24, ISSN: 0142-9612. 
Lee, PJ.; Ahmad, N.; Langer, R.; Mitragotri, S.; Prasad Shastri, V. (2006). Evaluation of 
chemical enhancers in the transdermal delivery of lidocaine. International Journal of 
Pharmaceutics, Vol. 308, No. 1-2, (February 2006), pp. 33-9, ISSN 0378-5173. 
Lee, S.; Snyder, B.; Newnham, RE.; Smith, NB. (2004). Noninvasive ultrasonic transdermal 
insulin delivery in rabbits using the light weight cymbal array. Diabetes Technology 
& Therapeutics; Vol. 6, No. 6, (December 2004), pp. 808-15, ISSN 1520-9156.  
Levenets, AA.; Shuvalov, SM.; Poliakov, AV. (1989). The effect of the disodium salt of 
ethylenediaminetetraacetate on the healing of experimental suppurative wounds. 
Stomatologiia (Mosk); Vol. 68, No. 5, (September-October 1989), pp. 14-16, ISSN 0039-
1735. 
Li GP, Liu ZG, Liao B & Zhong NS. (2009). Induction of Th1-Type Immune Response by 
Chitosan Nanoparticles Containing Plasmid DNA Encoding House Dust Mite 
Allergen Der p 2 for Oral Vaccination in Mice. Cellular and Molecular 
Immunology. Vol. 6, pp.45-50, ISSN: 1672-7681.   
Liu W, Hu M, Liu W, Xue C, Xu H & Yang X. (2008). Investigation of the carbopol gel of 
solid lipid nanoparticles for the transdermal iontophoretic delivery of 
www.intechopen.com
 Pharmacology 
 
428 
triamcinolone acetonide acetate. International Journal of Pharmaceutics. Vol.364, 
pp.135-141, ISSN: 0378-5173.  
Liu, H.; Li, S.; Pan, W.; et al. (2006). Investigation into the potential of low-frequency 
ultrasound facilitated topical delivery of Cyclosporin A. International Journal of 
Pharmaceutics, Vol. 326, No. 1-2, (December 2006), pp. 32-38, ISSN 0378-5173. 
Lopez-Castellano, A & Merino V.(2010). Chapter 2: Chemical enhancers. In: José Juan 
Escobar-Chávez (Ed), Current Technologies To Increase The Transdermal Delivery Of 
Drugs. Bentham Science Publishers Ltd. ISBN: 978-1-60805-191-5, Bussum, The 
Netherlands.  
Lu, MY.; Lee, D. & Rao, GS. (1992). Percutaneous absorption enhancement of leuprolide. 
Pharmaceutical Research, Vol. 9, No. 12, (December 1992), pp. 1575-9, ISSN 0724-8741. 
Lubbers, J.; Hekkenberg, RT. & Bezemer, RA. (2003). Time to threshold (TT), a safety 
parameter for heating by diagnostic ultrasound. Ultrasound In Medicine & Biology, 
Vol. 29, No. 5, (May 2003), pp. 755-64, ISSN 0301-5629. 
Luis, J.; Park, EJ.; Meyer, RJ.; Smith, NB. (2007). Rectangular cymbal arrays for improved 
ultrasonic transdermal insulin delivery. Journal of the Acoustical Society of America, 
Vol. 122, No. 4, (October 2007), pp. 2022-30, ISSN 0001-4966. 
Ma, X.; Fang, L.; Guo, J.; Zhao, N.; He, Z. (2010). Effect of counter-ions and penetration 
enhancers on the skin permeation of flurbiprofen. Journal of Pharmaceutical Sciences, 
Vol. 99, No. 4, (April 2010), pp. 1826-37, ISSN 0022-3549. 
Machet, L.; Pinton, J.; Patat, F.; Arbeille, B.; Pourcelot, L.; Vaillant, L. (1996). In vitro 
phonophoresis of digoxin across hairless mice and human skin: thermal effect of 
ultrasound. International Journal of Pharmaceutics, Vol. 133, No. 1-2, (May 1996), pp. 
39-45, ISSN 0378-5173. 
Maestrelli F, González-Rodríguez ML, Rabasco AM & Mura P. (2005). Preparation and 
characterisation of liposomes encapsulating ketoprofen–cyclodextrin complexes for 
transdermal drug delivery. International Journal of Pharmaceutics. Vol. 298, pp.55-67, 
ISSN: 0378-5173.  
Maloney M, Bezzant JL, Stephen RL. (1992). Iontophoreric administration of lidocaine 
anesthesia in office practice. Journal of Dermatologic Surgery & Oncology, Vol. 18, No. 
, (November 1992), 937-40, ISSN 0148-0812. 
Manosroi A, Kongkaneramit L & Manosroi J. (2004). Stability and transdermal absorption of 
topical amphotericin B liposome formulations. International Journal of Pharmaceutics. 
Vol. 270, pp.279-286, ISSN: 0378-5173.  
Matinian, AL.; Nagapetian, KH.; Amirian, SS.; et al. (1990). Papain phonophoresis in the 
treatment of suppurative wounds and inflammatory processes. Khirurgiia (Mosk), 
Vol. 9, (September 1990), pp. 74-6, ISSN 0023-1207. 
McCarron PA, Hall M. (2008). Incorporation of novel 1-alkylcarbonyloxymethyl prodrugs of 
5-fluorouracil into poly(lactide-co-glycolide) nanoparticles. International Journal of 
Pharmaceutics. Vol. 348, pp. 115-124, ISSN: 0378-5173.  
McElnay, JC.; Benson, HA.; Harland, R.; Hadgraft, J. (1993). Phonophoresis of methyl 
nicotinate. A preliminary study to elucidate the mechanism of action. 
Pharmaceutical Research, Vol. 10, No. 12, (December 1993), pp. 1726-31, ISSN 0724-
8741. 
www.intechopen.com
 Chemical and Physical Enhancers for Transdermal Drug Delivery 
 
429 
Mei Z, Chen H, Weng T, Yang Y & Yang X. (2003). Solid lipid nanoparticle and 
microemulsion for topical delivery of triptolide. European Journal of Pharmaceutics 
and Biopharmaceutics. Vol. 56, No. 189-196, ISSN: 0928-0987.  
Meidan, VM.; Walmsley, AD.; Docker, MF.; Irwin, WJ. (1999). Ultrasound enhanced 
diffusion into coupling gel during phonophoresis of 5-fluorouracil. International 
Journal of Pharmaceutics, Vol. 185, No. 2, (August 1999), pp. 205-13, ISSN 0378-5173. 
Mélot, M.; Pudney, PD.; Williamson, AM.; Caspers, PJ.; Van Der Pol, A.; Puppels, GJ. (2009). 
Studying the effectiveness of penetration enhancers to deliver retinol through the 
stratum cornum by in vivo confocal Raman spectroscopy. Journal of Controlled 
Release, Vol. 138, No. 1, (August 2009), pp. 32-9, ISSN 0168-3659.  
Menjoge AR, Kannan RM & Tomalia DA. (2010). Dendrimer-based drug and imaging 
conjugates: design considerations for nanomedical applications. Drug Discovery 
Today. Vol. 15, pp. 171-185, ISSN: 1359-6446. 
Menon, GK.; Price, LF.; Bommannan, B.; et al. (1994). Selective obliteration of the epidermal 
calcium gradient leads to enhanced lamellar body secretion. Journal of Investigative 
Dermatology, Vol. 102, No. 5, (May 1994), pp. 789-95, ISSN 0022-202X.  
Merino V, Kalia, YN, Guy RH. (1997). Transdermal therapy and diagnosis by iontophoresis. 
Trends in Biotechnology, Vol. 15, No. 8, (August 1997), pp. 288-90. ISSN 0167-7799. 
Merino V, Lopez A, Kalia YN, Guy RH. (1999). Electrorepulsion versus electroosmosis: 
effect of pH on the iontophoretic flux of 5-fluorouracil. Pharmaceutical Research, 
Vol. 16, No. 5, (May 1999), pp. 758-61, ISSN 0724-8741. 
Merino, G.; Kalia, YN. & Guy, RH. (2003). Ultrasound-Enhanced Transdermal Transport. 
Journal of Pharmaceutical Sciences, Vol. 92, No. 6, (June 2003), pp. 1125-37, ISSN 0022-
3549. 
Merino, V.; Micó-Albiñana, T.; Nácher, A.; Díez-Sales, O.; Herráez, M.; Merino-Sanjuán, M. 
(2008). Enhancement of nortriptyline penetration through human epidermis: 
influence of chemical enhancers and iontophoresis. Journal of Pharmacy & 
Pharmacology, Vol. 60, No. 4, (April 2008), pp. 415-20, ISSN 0022-3573. 
Meshali, MM.; Abdel-Aleem, HM.; Sakr, FM.; et al. (2008). In vitro phonophoresis: effect of 
ultrasound intensity and mode at high frequency on NSAIDs transport across 
cellulose and rabbit skin membranes. Pharmazie; Vol. 63, No. 1, (January 2008), pp. 
49-53, ISSN 0031-7144. 
Mittal A, Sara UV, Ali A, Aqil M. (2008). The effect of penetration enhancers on permeation 
kinetics of nitrendipine in two different skin models. Biology & Pharmaceutical 
Bulletin, Vol. 31, No. 9, (September 2008), pp. 1766-72, ISSN 0918-6158. 
Miyazaki, S.; Mizuoka, H.; Kohata, Y.; Takada, M. (1992). External control of drug release 
and penetration. Enhancing effect of ultrasound on the transdermal absorption of 
indomethacin from an oinment in rats. Chemical & Pharmaceutical Bulletin (Tokyo); 
Vol. 40, No. 10, (October 1992), pp. 2826-2830, ISSN 0009-2363. 
Montenegro, L.; Bucolo, C. & Puglisi, G. (2003). Enhancer effects on in vitro corneal 
permeation of timolol and acyclovir. Pharmazie, Vol. 58, No. 7, (July 2003), pp. 497-
501, ISSN 0031-7144. 
Monti, D.; Giannelli, R.; Chetoni, P.; Burgalassi, S. (2001). Comparison of the effect of 
ultrasound and of chemical enhancers on transdermal permeation of caffeine and 
morphine through hairless mouse skin in vitro. International Journal of 
Pharmaceutics, Vol. 229, No. 1-2, (October 2001), pp. 131-7, ISSN 0378-5173. 
www.intechopen.com
 Pharmacology 
 
430 
Morimoto, Y.; Mutoh, TM.; Ueda, H.; et al. (2005). Elucidation of the transport pathway in 
hairless rat skin enhanced by low-frequency sonophoresis based on the solute–
water transport relationship and confocal microscopy. Journal of Controlled Release, 
Vol. 103, (April 2005), pp. 587–97, ISSN 0168-3659.  
Mura, S.; Manconi, M.; Sinico, C.; Valenti, D.; Fadda, AM. (2009). Penetration enhancer-
containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil. 
International Journal of Pharmaceutics, Vol. 380, No. 1-2, (October 2009), pp. 72-9, 
ISSN 0378-5173. 
Murthy SN, Sen A, Zhao YL, Hui SW. (2004). Temperature influences the 
postelectroporation permeability state of the skin. Journal of Pharmaceutical 
Sciences, Vol. 93, No. 4, (April 2004), pp.908-15, ISSN 0928-0987. 
Mutalik S, Parekh HS, Davies NM, Udupa N. (2009). A combined approach of chemical 
enhancers and sonophoresis for the transdermal delivery of tizanidine 
hydrochloride. Drug Delivery, Vol. 16, No. 2, (February 2009), pp. 82-91, ISSN 1071-
7544. 
Nair, V. & Panchagnula, R. (2003). Poloxamer gel as vehicle for transdermal iontophoretic 
delivery of arginine vasopressin: evaluation of in vivo performance in rats. 
Pharmacology Research, Vol. 47, No. 6, (June 2003), pp. 555-62, ISSN 1043-6618. 
Ng, GY. & Wong, RY. (2008). Ultrasound phonophoresis of panax notoginseng improves the 
strength of repairing ligament: a rat model. Ultrasound In Medicine & Biology, Vol. 
34, No. 12, (December 2008), pp. 1919-23, ISSN 0301-5629. 
Niederhafner P, Šebestík J & Ježek J. (2005). Peptide dendrimers. Journal of Peptide Science. 
Vol. 11, pp. 757-788, ISSN: 1099-1387.  
Novak, FJ. (1964). Experirnental wansmission of lidocalne through intact skin by ultrasound. 
Archives of Physical Medicine & Rehabilitation, Vol. 64, (May 1996), pp. 231-2, ISSN 
0003-9993. 
Ogiso T, Iwaki M & Paku T. (1995). Effect of various enhancers on transdermal penetration 
of indomethacin and urea, and relationship between penetration parameters and 
enhancement factors. Journal of Pharmaceutical Sciences, Vol. 84, pp.482–88, ISSN: 
1520-6017. 
Okino M, Mohri H. (1987). Effects of a high-voltage electrical impulse and an anticancer 
drug on in vivo growing tumors. Japanese Journal of Cancer Research, Vol. 78, 
(December 1987), pp. 1319-1321, ISSN 0910-5050. 
Orlowskim S, Belehradek JJ, Paoletti C, Mir LM. (1988). Transient electropermeabilization of 
cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochemical 
Pharmacology, Vol. 34, (December 1988), pp. 4727-4733, ISSN 0006- 2952. 
Paliwal, S.; Menon, GK.; Mitragotri, S. (2006). Low-frequency sonophoresis: ultrastructural 
basis for stratum corneum permeability assessed using quantum dots. Journal of 
Investigative Dermatology, Vol. 126, No. 5, (May 2006), pp. 1095–1101, ISSN 0022-
202X.  
Parekh HS. (2007). The Advance of Dendrimers - A Versatile Targeting Platform for 
Gene/Drug Delivery. Current Pharmaceutical Design. Vol. 13, pp. 2837-2850, ISSN 
1381-6128.  
Park JH, Allen MG & Prausnitz MR. (2005). Biodegradable polymer microneedles: 
fabrication, mechanics and transdermal drug delivery. Journal of Controlled Release, 
Vol. 104, pp.51-66, ISSN 0168-3659.  
www.intechopen.com
 Chemical and Physical Enhancers for Transdermal Drug Delivery 
 
431 
Park JH. (2004). Polymeric microneedles for transdermal drug delivery. PhD Thesis. Georgia 
Institute of Technology. 
Perennes F, Marmiroli B, Matteucci M, Tormen M, Vaccari L & Fabrizio ED. (2006). Sharp 
beveled tip hollow microneedle arrays fabricated by LIGA and 3D soft lithography 
with polyvinyl alcohol. Journal of Micromechanics and Microengineering. Vol. 16, 
pp. 473-79, ISSN 1361-6439. 
Phillips, CA.  & Michniak, BB. (1995). Transdermal delivery of drugs with differing 
lipophilicities using Azone analogs as dermal penetration enhancers.  Journal of 
Pharmaceutical Sciences, Vol. 84, No. 12, (December 1995), pp. 1427-33, ISSN 0022-
3549. 
Pliquett U, Gallo S, Hui SW, GusbethCh, Neumann E. (2005). Local and transient structural 
changes in stratum corneum at high electric fields: contribution of Joule heating. 
Biolectrochemistry, Vol. 67, No.1, (September 2005), pp. 37-46, ISSN1567-5394. 
Pliquett U, GusbethCh, Nuccitelli R. (2008). A propagating heat wave model of skin 
electroporation. Journal of Theoretical Biology, Vol. 251, No. 2, (March 2008), pp. 
195-201, ISSN 0022-5193. 
Prausnitz MR, Bose VG, Langer R, Weaver JC. (1993). Electroporation of mammalian skin: a 
mechanism to enhance transdermal drug delivery. Proceeding of the National 
Academy of Sciences of the united states of American, Vol. 90, No. 22, (November 
1993), pp. 10504-8, ISSN 0027-8424. 
Ragelis, Siu. (1981). Tetracycline penetration into tissue by modified electro and 
phonophoretic methods. Antibiotiki, Vol. 26, No. 9, (September 1981), pp. 699-703, 
ISSN 0003-5637. 
Rizwan, M.; Aqil, M.; Talegaonkar, S.; Azeem, A.; Sultana, Y:, Ali, A. (2009). Enhanced 
transdermal drug delivery techniques: an extensive review of patents. Recent 
Patents on Drug Delivery & Formulations, Vol. 3, No. 2, pp. 105-24, ISSN1872-2113. 
Rodriguez-Justo O. & Moraes Â. M..(2011). Analysis of process parameters on the 
characteristics of liposomes prepared by ethanol injection with a view to process 
scale-up: Effect of temperature and batch volume.  Chemical Engineering Research 
and Design. Vol. 89, No. 6, (June 2011), pp. 785-792, ISSN: 0263-8762. 
Rojas-Oviedo I, Salazar-López RA, Reyes-Gasga J & Quirino-Barreda CT. (2007). Elaboration 
and structural analysis of aquasomes loaded with Indomethacin. European Journal of 
Pharmaceutical Sciences, Vol. 32, pp. 223-230, ISSN 0928-0987. 
Rornanenko, IM. & Araviiskii, RA. (1991). Comparative levels of amphoteficin B in the skin 
and subcutaneous fatty tissue after cutaneous application of amphotericin ointment 
by phonophoresis and with preliminary treatment by dimethyl sulfoxide. Antibiotiki i 
Khimioterapiia; Vol. 36, No. 9, (September 1991), pp. 29-31, ISSN 0235-2990. 
Rosim, GC.; Barbieri, CH.; Lanças, FM.; Mazzer, N. (2005). Diclofenac phonphoresis in 
human volunteers. Ultrasound in Medicine & Biology, Vol. 31, No. 3, (March 2005), 
pp. 337-43, ISSN 0301-5629. 
Rossier-Miranda FJ, Schroën CGPH & Boom RM. (2009). Colloidosomes: Versatile 
microcapsules in perspective. Colloids and Surfaces A: Physicochemical and 
Engineering Aspects. Vol. 343, pp. 43-49, ISSN: 0927-7757. 
Roxhed N, Samel B, Nordquist L, Griss P & Stemme G. (2008). Painless drug delivery 
through microneedle-based transdermal patches featuring active infusion. IEEE 
Transactions in Biomedical Engineering. Vol. 55 No.3, pp. 1063-71. ISSN: 0018-9294 
www.intechopen.com
 Pharmacology 
 
432 
Rzigalinski BA, Strobl JS. (2009). Cadmium-containing nanoparticles: Perspectives on 
pharmacology and toxicology of quantum dots. Toxicology and Applied 
Pharmacology. Vol. 238, pp. 280-288, ISSN: 0041-008X.  
Saliba, S.; Mistry, DJ.; Perrin, DH.; Gieck, J.; Weltman, A. (2007). Phonophoresis and the 
absorption of dexamethasone in the presence of an occlusive dressing. Journal of 
Athletic Training, Vol. 42, No. 3, (July-September 2007), pp. 349-54, ISSN 1062-6050. 
Sammoura F, Kang JJ, Heo YM, Jung TS & Lin L. (2007). Polymeric microneedle fabrication 
using a microinjection molding technique. Microsystem Technologies. Vol. 13, pp. 
517-22, ISSN: 1432-1858. 
Sanna V, Caria G & Mariani A. (2010). Effect of lipid nanoparticles containing fatty alcohols 
having different chain length on the ex vivo skin permeability of Econazole nitrate. 
Powder Technology. Vol. 201, pp. 32-36, ISSN: 0032-5910.   
Santander-Ortega MJ, Stauner T, Loretz B, Ortega-Vinuesa JL, Bastos-González D, Wenz G,  
Schaefer UF, Lehr CM. (2010). Nanoparticles made from novel starch derivatives 
for transdermal drug delivery. Journal of Controlled Release, Vol. 141, pp.85-92, ISSN 
0168-3659.   
Santoianni, P.; Nino, M. & Calabro, G. (2004). Intradermal drug delivery by low frequency 
sonophoresis (25KHz). Dermatol Online Journal, Vol. 10, No. 2, (October 2004), pp. 
24-33, ISSN 10872108. 
Senyiğit, T.; Padula, C.; Ozer, O.; Santi, P. (2009). Different approaches for improving skin 
accumulation of topical corticosteroids. International Journal of Pharmaceutics, Vol. 
380, No. 1-2, (October 2009), pp. 155-60, ISSN 0378-5173. 
Serikov, NP. (2007). Efficacy of ibuprofen (nurofen gel) ultraphonophoresis for pain in 
ostheoarthritis. Terapevticheskii arkhiv, Vol. 79, No. 5, pp. 79-81, ISSN 0040-3660. 
Shakeel F, Ramadan W. (2010). Transdermal delivery of anticancer drug caffeine from 
water-in-oil nanoemulsions. Colloids and Surfaces B: Biointerfaces. Vol. 75, pp. 356-
362, ISSN: 0927-7765. 
Sharma BB, Jain SK & Vyas SP. (1994). Topical liposome system bearing local anaesthetic 
lignocaine: preparation and evaluation. Journal of Microencapsulation. Vol. 11, pp. 
279-286, ISSN 0265-2048. 
Shelley WB, McConahy JC, Hesbacher EN. (1950). Effectiveness of antihistaminic compounds 
introduced into normal skin by iontophoresis. The Journal of Investigative 
Dermatology, Vol. 15, No. 5, (November 1950), pp. 343-4, ISSN 0022-202X. 
Shen, Q.; Li, W. & Li, W. (2007). The effect of clove oil on the transdermal delivery of 
ibuprofen in the rabbit by in vitro and in vivo methods. Drug Development & 
Industrial Pharmacy; Vol. 33, No. 12, (December 2007), pp. 1369-74, ISSN 0363-9045. 
Shim J, Seok Kang H, Park W, Han S, Kim J & Chang I. (2004). Transdermal delivery of 
mixnoxidil with block copolymer nanoparticles. Journal of Controlled Release, Vol. 97, 
pp.477-484, ISSN 0168-3659.   
Skauen, DM. (1974). Heat production by ultrasonic equipment. Journal of Pharmaceutical 
Sciences, Vol. 163, No. 1, (January 1974), pp. 114-6, ISSN 0022-3549. 
Smith, JC & Irwin, WJ. (2000). Ionisation and the effect of absorption enhancers on transport 
of salicylic acid through silastic rubber and human skin. International Journal of 
Pharmaceutics, Vol. 210, No. 1-2, (December 2000), pp. 69-82, ISSN 0378-5173. 
www.intechopen.com
 Chemical and Physical Enhancers for Transdermal Drug Delivery 
 
433 
Smith, NB.; Lee, S. & Shung, KK. (2003). Ultrasound-mediated transdermal in vivo transport 
of insulin with low profile cymbal arrays. Ultrasound in Medicine & Biology, Vol. 29, 
No. 8, (August 2003), pp. 1205-10, ISSN 0301-5629. 
Sonneville-Aubrun O.,  Simonnet J. -T. & Alloret F. L. (2004). Nanoemulsions: a new vehicle 
for skincare products. Advances in Colloid and Interface Science. Vols. 108-109, (20 
May 2004), pp. 145-149, ISSN 0001-8686. 
Soppimath KS, Aminabhavi TM, Kulkarni AR & Rudzinski WE. (2001). Biodegradable 
polymeric nanoparticles as drug delivery devices. Journal of Controlled Release, Vol. 
70, pp.1-20, ISSN 0168-3659. 
Stoeber B, Liepmann D. (2005). Arrays of hollow out-of-plane microneedles for drug delivery. 
Journal of Microelectronic systems. Vol. 14, No. 3, pp. 472-79, ISSN 0026-2692. 
Sung, KC.; Fang, J-Y.; Wang, JJ.; Hu O, Y-P.(2003).Transdermal delivery of nalbuphine and 
its prodrugs by electroporation. European Journal of Pharmaceutical Sciences, Vol. 18, 
No. 1, (January 2003), pp. 63–70, ISNN 0928-0987. 
Svenson S, Tomalia DA. (2005). Dendrimers in biomedical applications – reflections on the 
field. Advanced Drug Delivery Reviews, vol. 57, pp. 2106-2129, ISSN 0169-409X.  
Tachibana, K. & Tachibana, S. (1993). Use of ultrasound to enhance the local anesthetic effect 
of topically applied aqueous Lidocaine. Anesthesiology, Vol. 78, No. 6, (June 1993), 
pp. 1091-6, ISSN 0003-3022.  
Tachibana, K. & Tachibana, S. (1999). Application of ultrasound energy as a new drug 
delivery system. Nihon Yakurigaku Zasshi; Vol. 114, No. 1, (October 1999), pp. 138P-
141P,  ISSN 1340-2544. 
Tang, H.; Mitragotri, S.; Blankschtein, D.; Langer, R. (2001). Theoretical description of 
transdermal transport of hydrophilic permeants: application to low frequency 
sonophoresis. Journal of Pharmaceutical Sciences, Vol. 90, No. 5, (May 2001), pp. 543–
66, ISSN 0022-3549. 
Tartis MS, Kruse DE, Zheng H, Zhang H, Kheirolomoom A, Marik J & Ferrara KW. (2008). 
Dynamic microPET imaging of ultrasound contrast agents and lipid delivery. 
Journal of Controlled Release. Vol. 131: No. 3, (November, 2008) pp.160-166, ISSN 
0168-3659.  
Teeranachaideekul V, Souto EB, Junyaprasert VB & Müller RH. (2007). Cetyl palmitate-
based NLC for topical delivery of Coenzyme Q10 – Development, physicochemical 
characterization and in vitro release studies. European Journal of Pharmaceutical 
Sciences, Vol. 67, pp. 141-148, ISSN 0928-0987.  
Teo A L, Shearwood C, Kian C N, Jai L & Shabbiir M. (2005). Transdermal Microneedles for 
Drug Delivery Application. Materials Science and Engineering: B. Vol. 132, pp. 151-
54. ISSN 0921-5093. 
Tezel H, Dokka S, Kelly S, Hardee GE, Mitragotri S. (2004). Topical delivery of anti-sense 
oligonucleotides using low-frequency sonophoresis. Pharmaceutical Research, Vol. 
21, No. 12, (December 2004), pp. 2219-25, ISSN 0724-8741. 
Thote AJ, Gupta RB. (2005). Formation of nanoparticles of a hydrophilic drug using supercritical 
carbon dioxide and microencapsulation for sustained release. Nanomedicine: 
Nanotechnology, Biology and Medicine. Vol. 1, pp. 85-90, ISSN: 1549-9634.   
Tiwari, SB.; Pai, RM.; Udupa, N. (2004). Influence of ultrasound on the percutaneous 
absorption of ketorolac tromethamine in vitro across rat skin. Drug Delivery, Vol. 
11, No. 1, (January-February 2004), pp. 47-51, ISSN 1071-7544. 
www.intechopen.com
 Pharmacology 
 
434 
Ugazio E, Cavalli R & Gasco MR. (2002). Incorporation of cyclosporin A in solid lipid 
nanoparticles (SLN). International Journal of Pharmaceutics. Vol. 241, pp.341-344, 
ISSN: 0378-5173. 
Vaddi, HK.; Wang, LZ.; Ho, PC.; Chan, SY. (2001) Effect of some enhancers on the 
permeation of haloperidol through rat skin in vitro. International Journal of 
Pharmaceutics, Vol. 212, No. 2, (January 2001), pp. 247-55, ISSN 0378-5173. 
Walker, JJ. (1983). Ultrasound therapy for keloids. South African Medical Journal, Vol. 64, No. 
8, (August 1983), pp. 270, ISSN 0256-9574.  
Wang, YY.; Hong, CT.; Chiu, WT.; Fang, JY. (2001). In vitro and in vivo evaluations of 
topically applied capsaicin and nonivamide from hydrogels. International Journal of 
Pharmaceutics, Vol. 224, No. 1-2, (August 2001), pp. 89-104, ISSN 0378-5173. 
Wells, PN. (1977). Biomedical ultrasonics. Academic Press, pp. 421-30, New York. 
Wen Z, Fang L, He Z. (2009). Effect of chemical enhancers on percutaneous absorption of 
daphnetin in isopropyl myristate vehicle across rat skin in vitro. Drug Delivery, Vol. 
16, No. 4, (May 2009), pp. 214-23, ISSN 1071-7544. 
Williams, AC. & Barry, BW. (2004). Penetration enhancers. Advance Drug Delivery Reviews, 
Vol. 56, No. 5, (March 2004), 603–18, ISSN 0169-409X. 
Williams, AR. (1990). Phonophoresis: an in vivo evaluation using three topical anaesthetic 
preparations. Ultrasonics; Vol. 28, No. 3, (May 1990), pp. 137-41, ISSN 0041-624X. 
Xu DH, Zhang Q, Feng X, Xu X, Liang WQ. (2007). Synergistic effects of ethosomes and 
chemical enhancers on enhancement of naloxone permeation through human skin. 
Pharmazie, Vol. 62, No. 4, (April 2007), pp. 316-8, ISSN 0031-7144. 
Yang, JH.; Kim, DK.; Yun, MY.; Kim, TY.; Shin, SC. (2006). Transdermal delivery system of 
triamcinolone acetonide from a gel using phonophoresis. Archives of Pharmacal 
Research, Vol. 29, No. 5, (May 2006), pp. 412-27, ISSN 0253-6269.  
Yang, JH.; Kim, TY.; Lee, JH.; et al. (2008). Anti-hyperalgesic and anti-inflammatory effects 
of ketorolac tromethamine gel using pulsed ultrasound in inflamed rats. Archives of 
Pharmacal Research, Vol. 31, No. 4, (April 2008), pp. 511-17, ISSN 0253-6269.  
Yoo HS, Lee JE, Chung H, Kwon IC & Jeong SY. (2005). Self-assembled nanoparticles 
containing hydrophobically modified glycol chitosan for gene delivery. Journal of 
Controlled Release, Vol. 103, pp.235-243, ISSN 0168-3659.   
Zahn DJ, Trebotich D & Liepmann D. (2005). Microdialysis Microneedles for Continuous 
Medicla Monitoring. Biomedical Microdevices. Vol. 7, No. 1, pp. 59-69, ISSN 1387-
2176. 
Zhang, JY.; Fang, L.; Tan, Z.; Wu, J.; He, ZG. (2009). Influence of ion-pairing and chemical 
enhancers on the transdermal delivery of meloxicam. Drug Development & Industrial 
Pharmacy, Vol. 35, No. 6, (June 2009), pp. 663-70, ISSN 0363-9045. 
Zheng J, Zhu R, He Z, Cheng G, Wang H & Yao K. (2010). Synthesis and Characterization of 
PMMA/SiO2 Nanocomposites by In Situ Suspension Polymerization. Journal of 
Applied Polymer Science. Vol. 115, pp. 1975-1981, ISSN 0021-8995.  
Zimmermann S, Fienbork D, Stoeber B, Flouriders WA & Liepmann D. A. (2003). 
Microneedle-Base Glucose Monitor: Fabricated on a Wafer-Level Using In-Devoce 
Enzyme Immobilization. Proceedings of 12th International Conference on solid state 
sensors, actuators and Microsystems. pp.99-102.  
www.intechopen.com
Pharmacology
Edited by Dr. Luca Gallelli
ISBN 978-953-51-0222-9
Hard cover, 720 pages
Publisher InTech
Published online 14, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The history of pharmacology travels together to history of scientific method and the latest frontiers of
pharmacology open a new world in the search of drugs. New technologies and continuing progress in the field
of pharmacology has also changed radically the way of designing a new drug. In fact, modern drug discovery
is based on deep knowledge of the disease and of both cellular and molecular mechanisms involved in its
development. The purpose of this book was to give a new idea from the beginning of the pharmacology,
starting from pharmacodynamic and reaching the new field of pharmacogenetic and ethnopharmacology.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
José Juan Escobar-Chávez, Isabel Marlen Rodríguez-Cruz and Clara Luisa Domínguez-Delgado (2012).
Chemical and Physical Enhancers for Transdermal Drug Delivery, Pharmacology, Dr. Luca Gallelli (Ed.), ISBN:
978-953-51-0222-9, InTech, Available from: http://www.intechopen.com/books/pharmacology/chemical-and-
physical-enhancers-for-transdermal-drug-delivery
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
